WO2024099337A1 - Dérivés de thiadiazolyle, compositions et utilisations associées - Google Patents
Dérivés de thiadiazolyle, compositions et utilisations associées Download PDFInfo
- Publication number
- WO2024099337A1 WO2024099337A1 PCT/CN2023/130329 CN2023130329W WO2024099337A1 WO 2024099337 A1 WO2024099337 A1 WO 2024099337A1 CN 2023130329 W CN2023130329 W CN 2023130329W WO 2024099337 A1 WO2024099337 A1 WO 2024099337A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- independently
- compound
- certain embodiments
- optionally substituted
- Prior art date
Links
- 125000001113 thiadiazolyl group Chemical group 0.000 title abstract description 12
- 239000000203 mixture Substances 0.000 title description 132
- 150000001875 compounds Chemical class 0.000 claims abstract description 377
- 101100388059 Drosophila melanogaster PolQ gene Proteins 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 201000011510 cancer Diseases 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- -1 –N3 Chemical group 0.000 claims description 771
- 125000001424 substituent group Chemical group 0.000 claims description 251
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 166
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 166
- 125000005843 halogen group Chemical group 0.000 claims description 160
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 159
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 157
- 125000000217 alkyl group Chemical group 0.000 claims description 125
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 100
- 238000000034 method Methods 0.000 claims description 97
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 89
- 125000004043 oxo group Chemical group O=* 0.000 claims description 81
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 80
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 74
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 67
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 66
- 229910052805 deuterium Inorganic materials 0.000 claims description 66
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 63
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 58
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 56
- 125000001072 heteroaryl group Chemical group 0.000 claims description 55
- 125000003342 alkenyl group Chemical group 0.000 claims description 53
- 125000000304 alkynyl group Chemical group 0.000 claims description 53
- 150000003839 salts Chemical class 0.000 claims description 53
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 46
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 46
- 230000000155 isotopic effect Effects 0.000 claims description 46
- 239000012453 solvate Substances 0.000 claims description 44
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 43
- 150000001204 N-oxides Chemical class 0.000 claims description 43
- 239000000651 prodrug Substances 0.000 claims description 43
- 229940002612 prodrug Drugs 0.000 claims description 43
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 42
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 42
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 40
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 38
- 125000001188 haloalkyl group Chemical group 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 29
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 28
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 27
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 27
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 27
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 26
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 26
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 25
- 125000004429 atom Chemical group 0.000 claims description 24
- 125000004076 pyridyl group Chemical group 0.000 claims description 24
- 229910052702 rhenium Inorganic materials 0.000 claims description 24
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 17
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000004193 piperazinyl group Chemical group 0.000 claims description 16
- 125000003386 piperidinyl group Chemical group 0.000 claims description 16
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 15
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 15
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 14
- 125000002393 azetidinyl group Chemical group 0.000 claims description 14
- 125000002883 imidazolyl group Chemical group 0.000 claims description 14
- 125000003566 oxetanyl group Chemical group 0.000 claims description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 14
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 14
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 10
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims description 10
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 10
- 125000003725 azepanyl group Chemical group 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 125000000532 dioxanyl group Chemical group 0.000 claims description 8
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 5
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims description 5
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims description 5
- 230000002018 overexpression Effects 0.000 claims description 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 4
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 4
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- LTZZZXXIKHHTMO-UHFFFAOYSA-N 4-[[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenyl]methyl]-2H-phthalazin-1-one Chemical compound FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CCN(CC1)C(C1=CC=C(C=C1)F)=O LTZZZXXIKHHTMO-UHFFFAOYSA-N 0.000 claims description 4
- 102000000504 Tumor Suppressor p53-Binding Protein 1 Human genes 0.000 claims description 4
- 108010041385 Tumor Suppressor p53-Binding Protein 1 Proteins 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 4
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 4
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 3
- 229910052703 rhodium Inorganic materials 0.000 claims description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000005841 biaryl group Chemical group 0.000 claims 2
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 16
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 230000033616 DNA repair Effects 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 229910001868 water Inorganic materials 0.000 description 151
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 149
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 148
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 104
- 230000002829 reductive effect Effects 0.000 description 91
- 239000007787 solid Substances 0.000 description 83
- 239000000243 solution Substances 0.000 description 58
- 235000019439 ethyl acetate Nutrition 0.000 description 52
- 239000011541 reaction mixture Substances 0.000 description 49
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 239000007832 Na2SO4 Substances 0.000 description 42
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 42
- 229910052938 sodium sulfate Inorganic materials 0.000 description 42
- 239000012267 brine Substances 0.000 description 40
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 40
- 238000003818 flash chromatography Methods 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 33
- 238000002953 preparative HPLC Methods 0.000 description 32
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 30
- 239000003921 oil Substances 0.000 description 28
- 235000019198 oils Nutrition 0.000 description 28
- 239000004698 Polyethylene Substances 0.000 description 27
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 239000000741 silica gel Substances 0.000 description 23
- 229910002027 silica gel Inorganic materials 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 21
- 239000005457 ice water Substances 0.000 description 20
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 20
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 19
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 19
- 229910020323 ClF3 Inorganic materials 0.000 description 15
- 125000005842 heteroatom Chemical group 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 14
- 125000001246 bromo group Chemical group Br* 0.000 description 14
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 14
- 125000000168 pyrrolyl group Chemical group 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 11
- QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical class NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 11
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- YHOKLISWZGCCEV-UHFFFAOYSA-N (3-chloro-2-fluoro-6-methoxyphenyl)boronic acid Chemical compound ClC=1C(=C(C(=CC=1)OC)B(O)O)F YHOKLISWZGCCEV-UHFFFAOYSA-N 0.000 description 10
- AQKVPYJNRRKCJC-UHFFFAOYSA-N CC1=NC=C(C(O)=O)C(C(C(OC)=CC=C2)=C2F)=C1 Chemical compound CC1=NC=C(C(O)=O)C(C(C(OC)=CC=C2)=C2F)=C1 AQKVPYJNRRKCJC-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 229910019213 POCl3 Inorganic materials 0.000 description 10
- 230000006780 non-homologous end joining Effects 0.000 description 10
- 125000002971 oxazolyl group Chemical group 0.000 description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 description 10
- 125000000335 thiazolyl group Chemical group 0.000 description 10
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 125000002541 furyl group Chemical group 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- GDGIVSREGUOIJZ-UHFFFAOYSA-N 5-amino-3h-1,3,4-thiadiazole-2-thione Chemical compound NC1=NN=C(S)S1 GDGIVSREGUOIJZ-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 125000001715 oxadiazolyl group Chemical group 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 8
- 125000003831 tetrazolyl group Chemical group 0.000 description 8
- 125000001544 thienyl group Chemical group 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- NBGMELMIAOKZSD-UHFFFAOYSA-N 5-(difluoromethyl)-1,3,4-thiadiazol-2-amine Chemical class NC1=NN=C(C(F)F)S1 NBGMELMIAOKZSD-UHFFFAOYSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 7
- 238000006069 Suzuki reaction reaction Methods 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000001624 naphthyl group Chemical group 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 7
- 125000002053 thietanyl group Chemical group 0.000 description 7
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 150000001735 carboxylic acids Chemical class 0.000 description 6
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 6
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 125000001425 triazolyl group Chemical group 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 5
- AHYDSKZMHQDNEM-UHFFFAOYSA-N 2-[(5-amino-1,3,4-thiadiazol-2-yl)sulfanyl]ethanol Chemical compound NC1=NN=C(SCCO)S1 AHYDSKZMHQDNEM-UHFFFAOYSA-N 0.000 description 5
- URDJRGDXIXBMLP-UHFFFAOYSA-N 5-(1,1-difluoroethyl)-1,3,4-thiadiazol-2-amine Chemical compound CC(F)(F)C1=NN=C(N)S1 URDJRGDXIXBMLP-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- ZZEMYDVVPYLDBT-YFKPBYRVSA-N 2-[(3s)-oxolan-3-yl]oxyacetic acid Chemical compound OC(=O)CO[C@H]1CCOC1 ZZEMYDVVPYLDBT-YFKPBYRVSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- GLYQQFBHCFPEEU-UHFFFAOYSA-N 5-bromo-1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=C(Br)S1 GLYQQFBHCFPEEU-UHFFFAOYSA-N 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000006619 Stille reaction Methods 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 3
- VWRHSNKTSSIMGE-UHFFFAOYSA-N 5-ethylsulfanyl-1,3,4-thiadiazol-2-amine Chemical compound CCSC1=NN=C(N)S1 VWRHSNKTSSIMGE-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 3
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 150000005347 biaryls Chemical group 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000003979 granulating agent Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 3
- VAKBQHRUUZLSLW-UHFFFAOYSA-N methyl 4-chloro-6-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(C)C=C1Cl VAKBQHRUUZLSLW-UHFFFAOYSA-N 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 125000002577 pseudohalo group Chemical group 0.000 description 3
- 230000028617 response to DNA damage stimulus Effects 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- OJZNYUDKNVNEMV-UHFFFAOYSA-M trimethylstannanylium;hydroxide Chemical compound C[Sn](C)(C)O OJZNYUDKNVNEMV-UHFFFAOYSA-M 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- XOVMDVZAWWQSDC-UHFFFAOYSA-N (2-fluoro-6-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(F)=C1B(O)O XOVMDVZAWWQSDC-UHFFFAOYSA-N 0.000 description 2
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPCSARGPMNDYAO-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C(F)(F)F)C(F)=C1 FPCSARGPMNDYAO-UHFFFAOYSA-N 0.000 description 2
- 125000006016 2-bromoethoxy group Chemical group 0.000 description 2
- KDNFXUTYCAGURB-UHFFFAOYSA-N 2-fluoro-4-methoxy-1-(trifluoromethyl)benzene Chemical compound COC1=CC=C(C(F)(F)F)C(F)=C1 KDNFXUTYCAGURB-UHFFFAOYSA-N 0.000 description 2
- HSIDPCSFALZPHF-UHFFFAOYSA-N 2-n,2-n-dimethyl-1,3,4-thiadiazole-2,5-diamine Chemical compound CN(C)C1=NN=C(N)S1 HSIDPCSFALZPHF-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- XTLJKHBPNDOAGE-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)phenol Chemical compound OC1=CC=C(C(F)(F)F)C(F)=C1 XTLJKHBPNDOAGE-UHFFFAOYSA-N 0.000 description 2
- YBFSHOQLKBPYHL-UHFFFAOYSA-N 4-(2-methoxyphenyl)-6-methylpyridine-3-carboxylic acid Chemical compound COC1=CC=CC=C1C1=CC(C)=NC=C1C(O)=O YBFSHOQLKBPYHL-UHFFFAOYSA-N 0.000 description 2
- OWAFINPZJRSWRS-UHFFFAOYSA-N 4-[(5-amino-1,3,4-thiadiazol-2-yl)sulfanyl]butanenitrile Chemical compound NC1=NN=C(SCCCC#N)S1 OWAFINPZJRSWRS-UHFFFAOYSA-N 0.000 description 2
- RBFVGQWGOARJRU-UHFFFAOYSA-N 4-bromo-2-methylbutan-2-ol Chemical compound CC(C)(O)CCBr RBFVGQWGOARJRU-UHFFFAOYSA-N 0.000 description 2
- NPFSHIQNHIGKKL-UHFFFAOYSA-N 4-chloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C=N1 NPFSHIQNHIGKKL-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- NGOZZJNCZLAIPT-UHFFFAOYSA-N 5-(1,1,2,2,2-pentafluoroethyl)-1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=C(C(F)(F)C(F)(F)F)S1 NGOZZJNCZLAIPT-UHFFFAOYSA-N 0.000 description 2
- OHDCQMBWTWGBTH-UHFFFAOYSA-N 5-(2,2,2-trifluoroethoxymethyl)-1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=C(COCC(F)(F)F)S1 OHDCQMBWTWGBTH-UHFFFAOYSA-N 0.000 description 2
- WVADGUGNMCXLLM-UHFFFAOYSA-N 5-(2-methoxyethylsulfanyl)-1,3,4-thiadiazol-2-amine Chemical compound COCCSC1=NN=C(N)S1 WVADGUGNMCXLLM-UHFFFAOYSA-N 0.000 description 2
- MPGVDSYZFPJWIQ-UHFFFAOYSA-N 5-(ethoxymethyl)-1,3,4-thiadiazol-2-amine Chemical compound CCOCC1=NN=C(N)S1 MPGVDSYZFPJWIQ-UHFFFAOYSA-N 0.000 description 2
- FNEWTERNBPPUQE-UHFFFAOYSA-N 5-(fluoromethyl)-1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=C(CF)S1 FNEWTERNBPPUQE-UHFFFAOYSA-N 0.000 description 2
- ZXDPFAWIADNOFE-UHFFFAOYSA-N 5-amino-3h-1,3,4-thiadiazol-2-one Chemical class NC1=NN=C(O)S1 ZXDPFAWIADNOFE-UHFFFAOYSA-N 0.000 description 2
- KTWDTPBHCWJWGJ-UHFFFAOYSA-N 5-pyridin-4-yl-1,3,4-thiadiazol-2-amine Chemical compound S1C(N)=NN=C1C1=CC=NC=C1 KTWDTPBHCWJWGJ-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- YFWUOUVMSKJLQO-UHFFFAOYSA-N C(#N)C1=NC(=C(C(=O)O)C=C1)C1=C(C=CC=C1)OC Chemical compound C(#N)C1=NC(=C(C(=O)O)C=C1)C1=C(C=CC=C1)OC YFWUOUVMSKJLQO-UHFFFAOYSA-N 0.000 description 2
- MGCAZYXTPDSVGZ-UHFFFAOYSA-N CC(N=C1)=CC(C2=CC(Cl)=NC=C2OC)=C1C(O)=O Chemical compound CC(N=C1)=CC(C2=CC(Cl)=NC=C2OC)=C1C(O)=O MGCAZYXTPDSVGZ-UHFFFAOYSA-N 0.000 description 2
- WGRUJRARUWBPAE-UHFFFAOYSA-N CC(N=C1)=CC(C2=CC(Cl)=NC=C2OC)=C1C(OC)=O Chemical compound CC(N=C1)=CC(C2=CC(Cl)=NC=C2OC)=C1C(OC)=O WGRUJRARUWBPAE-UHFFFAOYSA-N 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- UAHCNUQVXRLPQW-UHFFFAOYSA-N COC1=C(C=CC=C1)C1=CC(=NC=C1C(=O)OC)C Chemical compound COC1=C(C=CC=C1)C1=CC(=NC=C1C(=O)OC)C UAHCNUQVXRLPQW-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 102100029094 DNA repair endonuclease XPF Human genes 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 description 2
- YZGQDNOIGFBYKF-UHFFFAOYSA-N Ethoxyacetic acid Chemical compound CCOCC(O)=O YZGQDNOIGFBYKF-UHFFFAOYSA-N 0.000 description 2
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 description 2
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 description 2
- 102100034553 Fanconi anemia group J protein Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 description 2
- 101000981336 Homo sapiens Nibrin Proteins 0.000 description 2
- 101000702606 Homo sapiens Structure-specific endonuclease subunit SLX4 Proteins 0.000 description 2
- 108010025026 Ku Autoantigen Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102100024403 Nibrin Human genes 0.000 description 2
- ATMGILZFBAHZMM-UHFFFAOYSA-N OC(=O)N1CCN2CCCC2C1 Chemical compound OC(=O)N1CCN2CCCC2C1 ATMGILZFBAHZMM-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-VKHMYHEASA-N S-propylene oxide Chemical compound C[C@H]1CO1 GOOHAUXETOMSMM-VKHMYHEASA-N 0.000 description 2
- 102100031003 Structure-specific endonuclease subunit SLX4 Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000005620 boronic acid group Chemical group 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 2
- 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- JQBAKJXNUBYIRR-UHFFFAOYSA-N methyl 2-chloro-1-oxidopyridin-1-ium-3-carboxylate Chemical compound COC(=O)C1=CC=C[N+]([O-])=C1Cl JQBAKJXNUBYIRR-UHFFFAOYSA-N 0.000 description 2
- DIXNVEHMCKSNLU-UHFFFAOYSA-N methyl 2-chloro-6-cyanopyridine-3-carboxylate Chemical compound COC(=O)c1ccc(nc1Cl)C#N DIXNVEHMCKSNLU-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000012354 sodium borodeuteride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000004089 sulfido group Chemical group [S-]* 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- SZLUJRHLIZAWGS-UWVGGRQHSA-N tert-butyl (7s,8as)-7-hydroxy-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCN2C[C@@H](O)C[C@H]21 SZLUJRHLIZAWGS-UWVGGRQHSA-N 0.000 description 2
- QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ICSOIMDWVVEKBW-UHFFFAOYSA-N (2,2,2-trifluoroethoxy)acetic acid Chemical compound OC(=O)COCC(F)(F)F ICSOIMDWVVEKBW-UHFFFAOYSA-N 0.000 description 1
- IWTBPDRQHIEPBQ-UHFFFAOYSA-N (2,3-difluoro-6-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(F)C(F)=C1B(O)O IWTBPDRQHIEPBQ-UHFFFAOYSA-N 0.000 description 1
- RIJYQJUSSTXMRQ-UHFFFAOYSA-N (2-chloro-5-methoxypyridin-4-yl)boronic acid Chemical compound COC1=CN=C(Cl)C=C1B(O)O RIJYQJUSSTXMRQ-UHFFFAOYSA-N 0.000 description 1
- RHODPGLYWAVVBN-UHFFFAOYSA-N (2-fluoro-6-methoxy-3-methylphenyl)boronic acid Chemical compound COC1=CC=C(C)C(F)=C1B(O)O RHODPGLYWAVVBN-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- XDPCNPCKDGQBAN-SCSAIBSYSA-N (3r)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 1
- GOIRRXGVYYWCGC-JTQLQIEISA-N (3s)-1-(4-methylphenyl)sulfonylpyrrolidin-3-ol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C[C@@H](O)CC1 GOIRRXGVYYWCGC-JTQLQIEISA-N 0.000 description 1
- URCCVQJLYSKFBQ-UHFFFAOYSA-N (5-amino-1,3,4-thiadiazol-2-yl)methanol Chemical compound NC1=NN=C(CO)S1 URCCVQJLYSKFBQ-UHFFFAOYSA-N 0.000 description 1
- FMBVAOHFMSQDGT-UHFFFAOYSA-N (5-chloro-2-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(Cl)C=C1B(O)O FMBVAOHFMSQDGT-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- WEGOLYBUWCMMMY-UHFFFAOYSA-N 1-bromo-2-propanol Chemical compound CC(O)CBr WEGOLYBUWCMMMY-UHFFFAOYSA-N 0.000 description 1
- FAVMSTGWFRDCRR-UHFFFAOYSA-N 1-chloro-2-fluoro-4-methoxybenzene Chemical compound COC1=CC=C(Cl)C(F)=C1 FAVMSTGWFRDCRR-UHFFFAOYSA-N 0.000 description 1
- NDCPERCVXDYEFU-UHFFFAOYSA-N 1-fluorocyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(F)CC1 NDCPERCVXDYEFU-UHFFFAOYSA-N 0.000 description 1
- SZCAORBAQHOJQI-UHFFFAOYSA-N 1-iodo-2-methoxyethane Chemical compound COCCI SZCAORBAQHOJQI-UHFFFAOYSA-N 0.000 description 1
- BJMSXWLXFYZHIU-UHFFFAOYSA-N 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1C=CC(B2OC(C)(C)C(C)(C)O2)=N1 BJMSXWLXFYZHIU-UHFFFAOYSA-N 0.000 description 1
- KJCIMSSFGUGTGA-UHFFFAOYSA-N 1-methylpiperazin-2-one Chemical compound CN1CCNCC1=O KJCIMSSFGUGTGA-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- LFHLEABTNIQIQO-UHFFFAOYSA-N 1H-isoindole Chemical compound C1=CC=C2CN=CC2=C1 LFHLEABTNIQIQO-UHFFFAOYSA-N 0.000 description 1
- XZYJNHZNHGUSNY-UHFFFAOYSA-N 2,2,2-trifluoro-n-methylethanamine Chemical compound CNCC(F)(F)F XZYJNHZNHGUSNY-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 1
- KURKJXZWCPWPFX-UHFFFAOYSA-N 2,2-difluoroacetyl chloride Chemical compound FC(F)C(Cl)=O KURKJXZWCPWPFX-UHFFFAOYSA-N 0.000 description 1
- LHOKYUDUAYXFGF-UHFFFAOYSA-N 2,2-difluoropent-4-enoic acid Chemical compound OC(=O)C(F)(F)CC=C LHOKYUDUAYXFGF-UHFFFAOYSA-N 0.000 description 1
- PMWGIVRHUIAIII-UHFFFAOYSA-N 2,2-difluoropropanoic acid Chemical compound CC(F)(F)C(O)=O PMWGIVRHUIAIII-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QXTRPGAMVIONMK-UHFFFAOYSA-N 2-amino-5-ethyl-1,3,4-thiadiazole Chemical compound CCC1=NN=C(N)S1 QXTRPGAMVIONMK-UHFFFAOYSA-N 0.000 description 1
- LZCMQBRCQWOSHZ-UHFFFAOYSA-N 2-bromo-2,2-difluoroacetic acid Chemical class OC(=O)C(F)(F)Br LZCMQBRCQWOSHZ-UHFFFAOYSA-N 0.000 description 1
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- KOHBEDRJXKOYHL-UHFFFAOYSA-N 2-methoxy-n-methylethanamine Chemical compound CNCCOC KOHBEDRJXKOYHL-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- DIQOUXNTSMWQSA-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1OC2CNC1C2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 1
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- FIUWHFOSVAXXFV-UHFFFAOYSA-N 3-ethoxy-2,2-difluoro-3-oxopropanoic acid Chemical compound CCOC(=O)C(F)(F)C(O)=O FIUWHFOSVAXXFV-UHFFFAOYSA-N 0.000 description 1
- MRWWWZLJWNIEEJ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-propan-2-yloxy-1,3,2-dioxaborolane Chemical compound CC(C)OB1OC(C)(C)C(C)(C)O1 MRWWWZLJWNIEEJ-UHFFFAOYSA-N 0.000 description 1
- XGCCUZRKNCUVJK-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxycyclohexan-1-ol Chemical compound CC(C)(C)[Si](C)(C)OC1CCC(O)CC1 XGCCUZRKNCUVJK-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- OEPBVXQEVBURGC-UHFFFAOYSA-N 4-bromo-2-fluoro-1-(trifluoromethyl)benzene Chemical compound FC1=CC(Br)=CC=C1C(F)(F)F OEPBVXQEVBURGC-UHFFFAOYSA-N 0.000 description 1
- CQPGDDAKTTWVDD-UHFFFAOYSA-N 4-bromobutanenitrile Chemical compound BrCCCC#N CQPGDDAKTTWVDD-UHFFFAOYSA-N 0.000 description 1
- DNMUMZLKDOZMEY-UHFFFAOYSA-N 4-methoxy-3-methylbenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1C DNMUMZLKDOZMEY-UHFFFAOYSA-N 0.000 description 1
- KVIZTDNKHOCNAM-UHFFFAOYSA-N 4-methylpiperazin-2-one Chemical compound CN1CCNC(=O)C1 KVIZTDNKHOCNAM-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- ZLDOCTTXAVVDHG-UHFFFAOYSA-N 5-(methoxymethyl)-1,3,4-thiadiazol-2-amine Chemical compound COCC1=NN=C(N)S1 ZLDOCTTXAVVDHG-UHFFFAOYSA-N 0.000 description 1
- LTEUXHSAYOSFGQ-UHFFFAOYSA-N 5-(trifluoromethyl)-1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=C(C(F)(F)F)S1 LTEUXHSAYOSFGQ-UHFFFAOYSA-N 0.000 description 1
- SZFUWUOHDRMCKD-UHFFFAOYSA-N 5-chloro-1h-pyridin-2-one Chemical compound OC1=CC=C(Cl)C=N1 SZFUWUOHDRMCKD-UHFFFAOYSA-N 0.000 description 1
- AVLUMBXGKFNNAS-UHFFFAOYSA-N 5-cyclopropyl-1,3,4-thiadiazol-2-amine Chemical compound S1C(N)=NN=C1C1CC1 AVLUMBXGKFNNAS-UHFFFAOYSA-N 0.000 description 1
- HMPUHXCGUHDVBI-UHFFFAOYSA-N 5-methyl-1,3,4-thiadiazol-2-amine Chemical compound CC1=NN=C(N)S1 HMPUHXCGUHDVBI-UHFFFAOYSA-N 0.000 description 1
- IGBPZWZBEPBBTR-UHFFFAOYSA-N 5-propan-2-yl-1,3,4-thiadiazol-2-amine Chemical compound CC(C)C1=NN=C(N)S1 IGBPZWZBEPBBTR-UHFFFAOYSA-N 0.000 description 1
- GJEZBVHHZQAEDB-UHFFFAOYSA-N 6-oxabicyclo[3.1.0]hexane Chemical compound C1CCC2OC21 GJEZBVHHZQAEDB-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102100027452 ATP-dependent DNA helicase Q4 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 description 1
- 101700002522 BARD1 Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102100035631 Bloom syndrome protein Human genes 0.000 description 1
- 108091009167 Bloom syndrome protein Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000025939 DNA Repair-Deficiency disease Diseases 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 102100039524 DNA endonuclease RBBP8 Human genes 0.000 description 1
- 108050008316 DNA endonuclease RBBP8 Proteins 0.000 description 1
- 102100029995 DNA ligase 1 Human genes 0.000 description 1
- 102100033195 DNA ligase 4 Human genes 0.000 description 1
- 108010032250 DNA polymerase beta2 Proteins 0.000 description 1
- 102100029765 DNA polymerase lambda Human genes 0.000 description 1
- 102100029766 DNA polymerase theta Human genes 0.000 description 1
- 108010093204 DNA polymerase theta Proteins 0.000 description 1
- 102100039116 DNA repair protein RAD50 Human genes 0.000 description 1
- 102100033934 DNA repair protein RAD51 homolog 2 Human genes 0.000 description 1
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 description 1
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 description 1
- 102100027828 DNA repair protein XRCC4 Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 102100027700 DNA-directed RNA polymerase I subunit RPA2 Human genes 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100033996 Double-strand break repair protein MRE11 Human genes 0.000 description 1
- LXXNWCFBZHKFPT-UHFFFAOYSA-N Ethyl 2-mercaptopropionate Chemical compound CCOC(=O)C(C)S LXXNWCFBZHKFPT-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000052930 Fanconi Anemia Complementation Group L protein Human genes 0.000 description 1
- 108700026162 Fanconi Anemia Complementation Group L protein Proteins 0.000 description 1
- 102100034552 Fanconi anemia group M protein Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101000580577 Homo sapiens ATP-dependent DNA helicase Q4 Proteins 0.000 description 1
- 101000785776 Homo sapiens Artemin Proteins 0.000 description 1
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 description 1
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 description 1
- 101000863770 Homo sapiens DNA ligase 1 Proteins 0.000 description 1
- 101000927810 Homo sapiens DNA ligase 4 Proteins 0.000 description 1
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 description 1
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 description 1
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 description 1
- 101000649315 Homo sapiens DNA repair protein XRCC4 Proteins 0.000 description 1
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- 101000865099 Homo sapiens DNA-directed DNA/RNA polymerase mu Proteins 0.000 description 1
- 101000729474 Homo sapiens DNA-directed RNA polymerase I subunit RPA1 Proteins 0.000 description 1
- 101000650600 Homo sapiens DNA-directed RNA polymerase I subunit RPA2 Proteins 0.000 description 1
- 101000591400 Homo sapiens Double-strand break repair protein MRE11 Proteins 0.000 description 1
- 101100119754 Homo sapiens FANCL gene Proteins 0.000 description 1
- 101000848187 Homo sapiens Fanconi anemia group M protein Proteins 0.000 description 1
- 101000998810 Homo sapiens Insulin-like peptide INSL6 Proteins 0.000 description 1
- 101000619640 Homo sapiens Leucine-rich repeats and immunoglobulin-like domains protein 1 Proteins 0.000 description 1
- 101000619643 Homo sapiens Ligand-dependent nuclear receptor-interacting factor 1 Proteins 0.000 description 1
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 description 1
- 101000578059 Homo sapiens Non-homologous end-joining factor 1 Proteins 0.000 description 1
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 description 1
- 101000720958 Homo sapiens Protein artemis Proteins 0.000 description 1
- 101001092206 Homo sapiens Replication protein A 32 kDa subunit Proteins 0.000 description 1
- 101001092125 Homo sapiens Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000654630 Homo sapiens Shieldin complex subunit 1 Proteins 0.000 description 1
- 101000632626 Homo sapiens Shieldin complex subunit 2 Proteins 0.000 description 1
- 101000632624 Homo sapiens Shieldin complex subunit 3 Proteins 0.000 description 1
- 101001095487 Homo sapiens Telomere-associated protein RIF1 Proteins 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- 101000904868 Homo sapiens Transcriptional regulator ATRX Proteins 0.000 description 1
- 101000804798 Homo sapiens Werner syndrome ATP-dependent helicase Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102100022172 Ligand-dependent nuclear receptor-interacting factor 1 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 125000004633 N-oxo-pyridyl group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102100028156 Non-homologous end-joining factor 1 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 description 1
- 102100025918 Protein artemis Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-GSVOUGTGSA-N R-propylene oxide Chemical compound C[C@@H]1CO1 GOOHAUXETOMSMM-GSVOUGTGSA-N 0.000 description 1
- 101710018890 RAD51B Proteins 0.000 description 1
- 102100035729 Replication protein A 70 kDa DNA-binding subunit Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100032737 Shieldin complex subunit 1 Human genes 0.000 description 1
- 102100028378 Shieldin complex subunit 2 Human genes 0.000 description 1
- 102100028385 Shieldin complex subunit 3 Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 1
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000006626 Weinreb Ketone synthesis reaction Methods 0.000 description 1
- 102100035336 Werner syndrome ATP-dependent helicase Human genes 0.000 description 1
- 102100036973 X-ray repair cross-complementing protein 5 Human genes 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- JMVOCSLPMGHXPG-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium Chemical compound [K+].[K+].[O-][Os]([O-])(=O)=O JMVOCSLPMGHXPG-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- DYAKYYSMROBYNG-UHFFFAOYSA-N ethyl 2,2-difluoro-2-trimethylsilylacetate Chemical compound CCOC(=O)C(F)(F)[Si](C)(C)C DYAKYYSMROBYNG-UHFFFAOYSA-N 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- MYGAJZBZLONIBZ-UHFFFAOYSA-N methyl 2-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1Cl MYGAJZBZLONIBZ-UHFFFAOYSA-N 0.000 description 1
- UWSWHAPVUHNFKD-UHFFFAOYSA-N methyl 3-chloropyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1Cl UWSWHAPVUHNFKD-UHFFFAOYSA-N 0.000 description 1
- JEJMDUMJSZTJTI-UHFFFAOYSA-N methyl 4,6-dichloropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C=C1Cl JEJMDUMJSZTJTI-UHFFFAOYSA-N 0.000 description 1
- QDXWZPBJWTYQNP-UHFFFAOYSA-N methyl 4-chloro-6-cyanopyridine-3-carboxylate Chemical compound COC(=O)c1cnc(cc1Cl)C#N QDXWZPBJWTYQNP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- GYLCBOOGXYLHKE-UHFFFAOYSA-N n,n-bis(4-methoxyphenyl)hydroxylamine Chemical compound C1=CC(OC)=CC=C1N(O)C1=CC=C(OC)C=C1 GYLCBOOGXYLHKE-UHFFFAOYSA-N 0.000 description 1
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000005482 norpinyl group Chemical group 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005889 octahydrochromenyl group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- BHDLTOUYJMTTTM-UHFFFAOYSA-N oxan-3-ol Chemical compound OC1CCCOC1 BHDLTOUYJMTTTM-UHFFFAOYSA-N 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 125000005961 oxazepanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- SCWLIHXXYXFUFV-UHFFFAOYSA-M sodium;2,2,3,3,3-pentafluoropropanoate Chemical compound [Na+].[O-]C(=O)C(F)(F)C(F)(F)F SCWLIHXXYXFUFV-UHFFFAOYSA-M 0.000 description 1
- CAQKQIYWKXZJGD-UHFFFAOYSA-M sodium;2-bromo-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Br CAQKQIYWKXZJGD-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- SZLUJRHLIZAWGS-VHSXEESVSA-N tert-butyl (7r,8as)-7-hydroxy-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCN2C[C@H](O)C[C@H]21 SZLUJRHLIZAWGS-VHSXEESVSA-N 0.000 description 1
- DFVRUHANEXOZGT-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-(methylamino)ethyl]carbamate Chemical compound CNCCN(C)C(=O)OC(C)(C)C DFVRUHANEXOZGT-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- IGELFKKMDLGCJO-UHFFFAOYSA-N xenon difluoride Chemical compound F[Xe]F IGELFKKMDLGCJO-UHFFFAOYSA-N 0.000 description 1
- 108010073629 xeroderma pigmentosum group F protein Proteins 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- the present disclosure relates to thiadiazolyl derivatives as PolQ inhibitors and pharmaceutical compositions thereof.
- the present disclosure also relates to methods for preparing the thiadiazolyl derivatives and their uses in the treatment of a PolQ-mediated disease, e.g., cancer containing a DNA repair defect.
- Double strand breaks can be repaired by one of three main pathways: homologous recombination (HR) , non-homologous end-joining (NHEJ) , and alternative NHEJ (alt-NHEJ) .
- HR homologous recombination
- NHEJ non-homologous end-joining
- alt-NHEJ alternative NHEJ
- An alt-NHEJ also known as microhomology-mediated end-joining (MMEJ) , is commonly considered as a "backup" DSB repair pathway when NHEJ or HR is compromised.
- MMEJ microhomology-mediated end-joining
- DDR DNA damage response
- PRP poly (ADP-ribose) polymerase
- DNA polymerase theta is a key protein involved in MMEJ. Kent et al. Nat. Struct. Mol. Biol. 2015, 22, 230-7; Mateos-Gomez et al. Nature 2015, 518, 254-7. PolQ is distinct among human DNA polymerases, comprising an N-terminal helicase domain (SF2 HEL308-type) and a C-terminal low-fidelity DNA polymerase domain (A-type) . Wood and D bountye, DNA Repair (Amst) . 2016, 44, 22-32.
- PolQ can carry out error-prone DNA synthesis at DNA damage sites through the alt-NHEJ pathway. It has been shown that the helicase domain of PolQ mediates the removal of a replication (RPA) protein from single-stranded (ssDNA) ends and stimulates annealing. This anti-recombinase activity of PolQ promotes the alt-NHEJ pathway. In addition, the helicase domain of PolQ contributes to microhomology-mediated strand annealing. Chan et al., PLoS Genet. 2010, 6, e1001005; Kawamura et al., Int. J. Cancer 2004, 109, 9-16.
- PolQ can promote end joining in the alt-NHEJ pathway by employing this annealing activity when ssDNA overhangs contain >2 base pair (bp) of microhomology. Kent et al., Elife 2016, 5, e13740; Kent, et al., Nat. Struct. Mol. Biol. 2015, 22, 230-7.
- This reannealing activity is achieved through coupled actions of Rad51 interaction, followed by ATPase-mediated displacement of Rad51 from DSB damage sites. Once annealed, the polymerase domain extends the ssDNA ends and fills the remaining gaps.
- PolQ The expression of PolQ is low in normal cells but significantly over-expressed in subsets of HRD ovarian, uterine, and breast cancers with associated poor prognosis. Higgins et al., Oncotarget 2010, 1, 175-84; Lemee et al., Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 13390-5; Ceccaldi et al., Nature 2015, 518, 258-62. Recent studies suggest that cancer cells with deficiency in HR, NHEJ, or ATM are highly dependent on PolQ expression. Ceccaldi et al., 2015, supra; Mateos-Gomez et al., 2015, supra; Wyatt et al., Mol.
- PolQ inhibition could conceivably prevent the MMEJ-dependent functional reversion of BRCA1-or BRCA2-mutations that underlies the emergence of cisplatin and PARPi resistance in tumors. Zatreanu et al., Nat. Commun. 2021, 12, 3636) . Therefore, PolQ is an attractive target for synthetic lethal therapy in cancer containing a DNA repair defect.
- composition comprising a compound of Formula (I) , or pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; and a pharmaceutically acceptable carrier.
- a method of treating cancer in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I) , or pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof.
- a method of inhibiting a PolQ comprising contacting the PolQ with an effective amount of a compound of Formula (I) , or pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof.
- each divalent linking group includes both the forward and backward forms of the divalent linking group.
- —NR (CR’R”) includes both the forward and backward forms of the divalent linking group.
- CR’R includes both the forward and backward forms of the divalent linking group.
- CR’R includes both the forward and backward forms of the divalent linking group.
- CR’R includes both the forward and backward forms of the divalent linking group.
- CR’R –includes both –NR (CR’R”) –and – (CR’R”) NR–.
- the Markush variables listed for that group are understood to be linking groups.
- alkyl or “aryl” then it is understood that the “alkyl” or “aryl” represents a linking alkylene group or arylene group, respectively.
- substituted means that an atom or group of atoms formally replaces hydrogen as a “substituent” attached to another group.
- substituted refers to any level of substitution, e.g., mono-, di-, tri-, tetra-, or penta-substitution, where such substitution is permitted.
- the substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency.
- optionally substituted means unsubstituted or substituted.
- substituted means that a hydrogen atom is removed and replaced by a substituent.
- a single divalent substituent e.g., oxo
- substituents include, but are not limited to, D, halo, oxo, C 1 -C -6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl-NR c R d , – (CH 2 CH 2 O) o C 1 -C 6 alkyl wherein o is 1-10; C 2-6 alkenyl-NR c R d , C 2-6 alkynyl-NR c R d , –OC 2-6 alkyl-NR c R d , –CN, –NO 2 , –N 3 , –OR a , –SR a , –C (O) R b , –C (O) NR c R d , –CH 2 C (
- C n -C m indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons.
- C 1 -C 6 alkyl is specifically intended to individually disclose methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, and C 6 alkyl.
- C 0 alkyl refers to a covalent bond.
- stable refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent.
- alkyl is meant to refer to a saturated hydrocarbon group which is straight-chained or branched.
- An alkyl group can contain from about 1 to about 20, from about 2 to about 20, from about 1 to about 10, from about 1 to about 8, from about 1 to about 6, from about 1 to about 4, or from about 1 to about 3 carbon atoms.
- alkyl can include any number of carbons, such as C 1 -C 2 alkyl, C 1 -C 3 alkyl, C 1 -C 4 alkyl, C 1 -C 5 alkyl, C 1 -C 6 alkyl, C 1 -C 7 alkyl, C 1 -C 8 alkyl, C 1 -C 9 alkyl, C 1 -C 10 alkyl, C 2 -C 3 alkyl, C 2 -C 4 alkyl, C 2 -C 5 alkyl, C 2 -C 6 alkyl, C 3 -C 4 alkyl, C 3 -C 5 alkyl, C 3 -C 6 alkyl, C 4 -C 5 alkyl, C 4 -C 6 alkyl, and C 5 -C 6 alkyl.
- C 1 -C 2 alkyl C 1 -C 3 alkyl, C 1 -C 4 alkyl, C 1 -C 5 alkyl, C 1 -C 6 alkyl
- C 1 -C 8 as in C 1 -C 8 alkyl is defined to identify the group as having 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms in a linear or branched arrangement.
- alkyl groups include, but are not limited to, methyl (Me) , ethyl (Et) , propyl (e.g., n-propyl and isopropyl) , butyl (e.g., n-butyl, isobutyl, and t-butyl) , pentyl (e.g., n-pentyl, isopentyl, and neopentyl) , hexyl, heptyl, and octyl.
- alkenyl is meant to refer to a hydrocarbon group having one or more double carbon-carbon bonds.
- Alkenyl can include any number of carbons, such as C 2 -C 3 alkenyl, C 2 -C 4 alkenyl, C 2 -C 5 alkenyl, C 2 -C 6 alkenyl, C 2 -C 7 alkenyl, C 2 -C 8 alkenyl, C 2 -C 9 alkenyl, C 2 -C 10 alkenyl, C 3 -C 4 alkenyl, C 3 -C 5 alkenyl, C 3 -C 6 alkenyl, C 4 -C 5 alkenyl, C 4 -C 6 alkenyl and C 5 -C 6 alkenyl.
- alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.
- alkynyl is meant to refer to a hydrocarbon group having one or more triple carbon-carbon bonds.
- Alkynyl can include any number of carbons, such as C 2 -C 3 alkynyl, C 2 -C 4 alkynyl, C 2 -C 5 alkynyl, C 2 -C 6 alkynyl, C 2 -C 7 alkynyl, C 2 -C 8 alkynyl, C 2 -C 9 alkynyl, C 2 -C 10 alkynyl, C 3 -C 4 alkynyl, C 3 -C 5 alkynyl, C 3 -C 6 alkynyl, C 4 -C 5 alkynyl, C 4 -C 6 alkynyl, and C 5 -C 6 alkynyl.
- alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, and
- haloalkyl is meant to refer to an alkyl group having one or more halo as substituents.
- haloalkyl groups include, but are not limited to, –CF 3 , –C 2 F 5 , –CHF 2 , –CH 2 F, –CCl 3 , –CHCl 2 , and –C 2 Cl 5 .
- aryl is meant to refer to an unsubstituted or substituted monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings) aromatic hydrocarbon.
- aryl groups have from about 6 to about 20 carbon atoms.
- aryl groups have from about 6 to about 14 carbon atoms.
- aryl groups have from about 6 to about 10 carbon atoms. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, and indenyl.
- Cycloalkyl is meant to refer to an unsubstituted or substituted nonaromatic carbocycle.
- Cycloalkyl groups can include mono-or polycyclic (e.g., having 2, 3, or 4 rings) ring systems, including fused rings, spirocyclic rings, and bridged rings (e.g., a bridged bicycloalkyl group) .
- cycloalkyl groups can have from about 3 to about 20 carbon atoms, from about 3 to about 14 carbon atoms, from about 3 to about 10 carbon atoms, or from about 3 to 7 carbon atoms. Cycloalkyl groups can further have 0, 1, 2, or 3 double bonds and/or 0, 1, or 2 triple bonds.
- the cycloalkyl is C 3 -C 7 monocyclic cycloalkyl.
- the cycloalkyl is C 4- C 10 spiro or bridged cycloalkyl.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcaranyl, cubanyl, adamantanyl, bicyclo [1.1.1] pentyl, bicyclo [2.1.1] hexyl, bicyclo [2.2.1] heptanyl, bicyclo [3.1.1] -heptanyl, bicyclo [2.2.2] octanyl, and spiro [3.3] heptanyl.
- heteroaryl is meant to refer to an unsubstituted or substituted aromatic heterocycle having at least one heteroatom ring member such as boron, sulfur, oxygen, or nitrogen.
- Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3, or 4 fused rings) systems. Any ring-forming N atom in a heteroaryl group can also be oxidized to form an N-oxo moiety.
- heteroaryl groups include, are not limited to, pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuryl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1, 2, 4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, and indolinyl.
- the heteroaryl group has from about 1 to about 20 carbon atoms or from about 3 to about 20 carbon atoms. In certain embodiments, the heteroaryl group contains from about 3 to about 14, from about 3 to about 7, about 5, or about 6 ring-forming atoms. In certain embodiments, the heteroaryl group has from about 1 to about 4, from about 1 to about 3, about 1, or about 2 heteroatoms.
- Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having 2 fused rings) systems.
- heterocycloalkyl Included in heterocycloalkyl are monocyclic and polycyclic 3-10, 4-10, 3-7, 4-7, and 5-6 membered heterocycloalkyl groups.
- Heterocycloalkyl groups can also include spirocyclic and bridged rings (e.g., a 5-10 membered bridged biheterocycloalkyl) .
- the heterocycloalkyl group contains 0 to 3 double bonds. In certain embodiments, the heterocycloalkyl group contains 0 to 2 double bonds.
- heterocycloalkyl moieties that have one or more aromatic rings fused to the non-aromatic heterocyclic ring, for example, benzo or thienyl derivatives of piperidine, morpholine, azepine, etc.
- the heterocycloalkyl group contains 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, 3 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms.
- the heterocycloalkyl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms or 1 heteroatom.
- the heterocycloalkyl is a monocyclic 4-6 membered heterocycloalkyl having 1 or 2 heteroatoms.
- heterocycloalkyl groups include, but are not limited to, pyrrolidin-2-onyl, l, 3-isoxazolidin-2-onyl, pyranyl, tetrahydropyranyl, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazepinyl, 1, 2, 3, 4-tetrahydroisoquinolinyl, azabicyclo [3.1.0] hexanyl, diazabicyclo [3.
- heterocycloalkyl is meant to refer to any three to ten membered monocyclic or bicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N, and S.
- the heterocycloalkyl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.
- heterocycloalkyl groups include, but are not limited to, azepanyl, aziridinyl, azetidinyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperazinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, oxetanyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, and piperazinyl.
- halo or halogen is meant to refer to fluoro, chloro, bromo, and iodo.
- alkoxy is meant to refer to an –O-alkyl group.
- alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy) , and t-butoxy.
- hydroxylalkyl is meant to refer to an alkyl group substituted by —OH.
- cyanoalkyl is meant to refer to an alkyl group substituted by —CN.
- alkoxyalkyl is meant to refer to an alkyl group substituted by an alkoxy group.
- haloalkoxy is meant to refer to an —O- (haloalkyl) group.
- arylalkyl or “aralkyl” is meant to refer to alkyl substituted by aryl.
- An example of the arylalkyl group is benzyl.
- cycloalkylalkyl is meant to refer to alkyl substituted by cycloalkyl.
- heteroarylalkyl is meant to refer to alkyl substituted by heteroaryl.
- heterocycloalkylalkyl is meant to refer to alkyl substituted by heterocycloalkyl.
- the compounds of the disclosure, and salts thereof are substantially isolated.
- substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which was formed or detected.
- Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99%by weight of the compound of the disclosure, or a salt thereof.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable excipient refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
- solvate refers to a physical association of a compound with one or more solvent molecules.
- subject refers to an animal, including, but not limited to, a primate (e.g., human) , cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse.
- primate e.g., human
- subject and patient are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject. In one embodiment, the subject is a human.
- treating or “treatment” of a disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof) .
- “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject.
- “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom) , physiologically, (e.g., stabilization of a physical parameter) , or both.
- “treating” or “treatment” refers to delaying the onset of the disease or disorder.
- isotopic variant refers to a compound that contains proportions of isotopes at one or more of the atoms that constitute such compound that is greater than natural abundance.
- an “isotopic variant” of a compound can be radiolabeled, that is, contain one or more radioactive isotopes, or can be labeled with non-radioactive isotopes such as for example, deuterium ( 2 H or D) , carbon-13 ( 13 C) , nitrogen-15 ( 15 N) , or the like.
- any hydrogen may be 2 H/D
- any carbon may be 13 C
- any nitrogen may be 15 N, and that the presence and placement of such atoms may be determined within the skill of the art.
- ring A is C 5 -C 10 cycloalkyl, 5-10 membered heterocycloalkyl, C 6 -C 10 aryl, or 5-10 membered heteroaryl;
- Cy is C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, or 5-10 membered heteroaryl;
- n is an integer of 1, 2, 3, 4, or 5;
- n is an integer of 1, 2, 3, 4, or 5;
- each R 1 is independently H, D, –CN, –NO 2 , –N 3 , oxo, –SF 5 , halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, –NR C R D , –OR A , –SR A , –NR C OR A , –C (O) R B , –C (O) NR C R D , –C (O) OR A , –OC (O) R B , –NR C C (O) R B , –S (O) R B , –S (O) 2 R B , –S (O) NR C R D , –NR C S (O) 2 R D , –S (O) 2
- R 1 two R 1 together with the atom (s) to which they are attached form oxo, C 3 -C 7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, or 5-6 membered heteroaryl; wherein the cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl are each optionally substituted by 1, 2, 3, or 4 substituents, each of which is independently R 1A ;
- each R 1A is independently D, halo, –CN, –OH, –NH 2 , –NO 2 , –SF 5 , oxo, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, –NR c R d , –OR a , –SR a , –C (O) R b , –C (O) NR c R d , –C (O) OR a , –OC (O) R b , –OC (O) NR c R d , –NR c C (O) R b , –NR c C (O) NR c R d , –NR c C (O) OR a , –S (O)
- each R 2A is independently D, halo, –CN, –OH, –NH 2 , –NO 2 , –N 3 , oxo, C 1 -C 6 alkyl, –OC 1 -C 6 alkyl, C 1 -C 6 haloalkyl, –OC 1 -C 6 haloalkyl, –NHC 1 -C 3 alkyl, –N (C 1 -C 3 alkyl) 2 , C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, or 4-6 membered heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl are each optionally substituted with D, halo, –CN, –OH, –NH 2 , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl,
- each R 2B is independently D, halo, oxo, –CN, –OH, –NH 2 , –NO 2 , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, –O-C 1 -C 6 alkyl, or –O-C 1 -C 6 haloalkyl;
- R 3 is:
- each R 4 is independently H, D, halo, –CN, –NO 2 , –N 3 , oxo, –OR A1 , –OR A2 , C 1 -C 4 alkyl, –C (O) R B , –C (O) NR C R D , –C (O) OR A , –C (O) NR C S (O) R B , –C (O) NR C S (O) 2 R B , –OC (O) R B , –OC (O) NR C R D , –NR C R D , –NR C C (O) R B , –NR C C (O) NR C R D , –NR C C (O) OR A , —SR A , –S (O) R B , –S (O) 2 R B , –S (O) NR C R D , –NR C S (O) 2 R D , –S (O
- R A1 is independently H, D, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl; wherein the alkyl, alkenyl, and alkynyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 11 ;
- each R 11 is independently D, –CN, –N 3 , halo, –NO 2 , oxo, –OR a , –SR a , –NR c R d , –C (O) R b , –C (O) NR c R d , –C (O) OR a , –OC (O) R b , –OC (O) NR c R d , –NR c C (O) R b , –NR c C (O) NR c R d , –NR c C (O) OR a , –S (O) R b , –S (O) 2 R b , –S (O) NR c R d , –NR c S (O) 2 R d , –S (O) 2 NR c R d , –NR c S (O) 2 NR c R d ,
- R A2 is C 3 -C 14 cycloalkyl, 4-14 membered heterocycloalkyl, C 6 -C 14 aryl, or 5-14 membered heteroaryl; wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ;
- each R 12 is independently H, D, halo, –CN, –N 3 , –NO 2 , oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 10 aryl, C 3 -C 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, –OR a , –SR a , –C (O) R b , –C (O) NR c R d , –C (O) OR a , –OC (O) R b , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –NR c C (O) NR c R d , –NR c C (O) OR a , –B (OR e ) (
- each R 5 , R 6 , and R 7 is independently H, D, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 7 cycloalkyl, 4-7 membered heterocycloalkyl, or phenyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, and phenyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, halo, –CN, –NO 2 , –N 3 , oxo, –NR C R D , –OR A , –SR A , –C (O) R B , –C (O) NR C R D , –OC (O) NR C R D , –NR C C (O) R B , –NR C C (O) NR C R D , –NR
- each R 8 is independently C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, or 5-10 membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A ;
- each R 9 and R 10 is independently H, D, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 halo
- each R A is independently H, D, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocyclo-alkylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1
- each R B is independently H, D, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, hetero-cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ;
- each R B1 is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, C 0 -C 4 alkyl-C 3 -C 10 cycloalkyl, C 0 -C 4 alkyl-4-10 membered heterocycloalkyl, C 0 -C 4 alkyl-C 6 -C 10 aryl, C 0 -C 4 alkyl-5-10 membered heteroaryl, –SF 5 , –C (O) R b , –OC (O) NR c R d , –OR a , –NR c R d , –NR c C (O) R b ,
- each R C and R D is independently H, D, –CN, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C
- R C and R D together with the N atom to which they are attached form 4-7 membered heterocycloalkyl, optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, oxo, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1 -C 4 alkyl) 2 , halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, or –OC 1 -C 4 haloalkyl;
- each R a and R a1 is independently H, D, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, phenyl, C 3 -C 7 cycloalkyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, heteroaryl, and heterocycloalkyl are each optionally substituted with 1, 2, 3, 4 or 5 substituents, each of which is independently D, halo, –OH, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1 -C 4 alkyl) 2 , C 1 -C 4 alkyl, –OC 1 -C 4 alkyl, C 1 -C 4 haloalkyl, or —OC 1 -C 4 haloalkyl
- each R b and R b1 is independently H, D, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, phenyl, C 3- C 7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl; wherein the alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1
- each R c and R d is independently H, D, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocyclo-alkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl, or biheteroaryl; wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl,
- R c and R d together with the N atom to which they are attached form 4-7 membered heterocycloalkyl, optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1 -C 4 alkyl) 2 , halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 4 hydroxyalkyl, C 1 -C 4 cyanoalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 1 -C 4 alkoxy-C 1 -C 4 alkyl, or C 1 -C 4 alkoxy-C 1 -C 4 alkoxy;
- each R E and R e is independently H, D, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, (C 1 -C 4 alkoxy) -C 1 -C 4 alkyl, C 2 -C 4 alkynyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl-C 1 -C 4 alkyl, C 3 -C 10 cycloalkyl-C 1 -C 4 alkyl, 5-10 membered heteroaryl-C 1 -C 4 alkyl, or 4-10 membered heterocycloalkyl-C 1 -C 4 alkyl;
- each R F and R f is independently H, D, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 3 -C 10 cycloalkyl, or 4-10 membered heterocycloalkyl;
- each R G , R H , R I , R g , R h , and R i is independently C 1 -C 4 alkyl or phenyl.
- the compound provided herein is neither 2'-chloro-5'-methoxy-6-methyl-N- (5- (2-oxo-2- (pyrrolidin-1-yl) ethyl) -1, 3, 4-thiadiazol-2-yl) - [4, 4'-bipyridine] -3-carboxamide nor 2'-chloro-N- (5- (2- (dimethylamino) -2-oxoethyl) -1, 3, 4-thiadiazol-2-yl) -5'-methoxy-6-methyl- [4, 4'-bipyridine] -3-carboxamide.
- ring A is C 5 -C 10 cycloalkyl, 5-10 membered heterocycloalkyl, C 6 -C 10 aryl, or 5-10 membered heteroaryl.
- ring A is C 5 -C 10 cycloalkyl. In certain embodiments, ring A is saturated C 5 -C 10 cycloalkyl or partially unsaturated C 5 -C 10 cycloalkyl. In certain embodiments, ring A is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl.
- ring A is 5-10 membered heterocycloalkyl. In certain embodiments, ring A is saturated 5-10 membered heterocycloalkyl or partially unsaturated 5-10 membered heterocycloalkyl. In certain embodiments, ring A is azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, dioxanyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, pyridin-2 (1H) -onyl, 1, 2, 4-triazin-5 (4H) -onyl, pyrimidin-2 (1H) -onyl, or pyrazin-2 (1H) -onyl. In certain embodiments, ring A is pyridin-2 (1H) -onyl.
- ring A is C 6 -C 10 aryl. In certain embodiments, ring A is phenyl or naphthyl.
- ring A is 5-10 membered heteroaryl. In certain embodiments, ring A is monocyclic 5-10 membered heteroaryl. In certain embodiments, ring A is 5-membered heteroaryl. In certain embodiments, ring A is pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, tetrazolyl, pyrazolyl, 1, 2, 4-triazolyl, 1, 2, 3-triazolyl, thiadiazolyl, or oxadiazolyl. In certain embodiments, ring A is imidazolyl. In certain embodiments, ring A is 6-membered heteroaryl.
- ring A is pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl. In certain embodiments, ring A is pyridinyl. In certain embodiments, ring A is pyridazinyl. In certain embodiments, ring A is 7-10 membered heteroaryl. In certain embodiments, ring A is 9-membered heteroaryl. In certain embodiments, ring A is [1, 2, 4] triazolo [1, 5-a] pyridinyl or imidazo [1, 2-a]pyridinyl.
- ring A is 5-or 6-membered heteroaryl. In certain embodiments, ring A is imidazolyl, pyridinyl, or pyridazinyl. In certain embodiments, ring A is imidazolyl or pyridinyl.
- the moiety has the structure of
- each X 1 , X 2 , X 3 , and X 4 is independently N or CR 1 ;
- each X 5 is independently NR 1 , O, or S;
- each R 1 is as defined herein.
- the moiety has the structure of wherein X 1 , X 2 , X 3 , and X 4 are each as defined herein.
- one of X 1 , X 2 , X 3 , and X 4 is N; and the remaining three are each independently CR 1 , wherein R 1 is as defined herein.
- two of X 1 , X 2 , X 3 , and X 4 are each N; and the remaining two are each independently CR 1 , wherein R 1 is as defined herein.
- X 1 , X 2 , X 3 , and X 4 are each independently CR 1 , wherein R 1 is as defined herein.
- the moiety has the structure of wherein R 1 , X 1 , and X 4 are each as defined herein.
- the moiety has the structure of wherein X 1 , X 2 , and X 3 are each as defined herein.
- one of X 1 , X 2 , and X 3 is N; and the remaining two are each independently CR 1 , wherein R 1 is as defined herein.
- two of X 1 , X 2 , and X 3 are N; and the remaining one is CR 1 , wherein R 1 is as defined herein.
- X 1 , X 2 , and X 3 are each independently CR 1 , wherein R 1 is as defined herein.
- the moiety has the structure of wherein each X 1 , X 3 , and X 5 is as defined herein.
- each X 1 and X 3 is independently CR 1 ; and X 5 is NR 1 , O or S; wherein each R 1 is as defined herein.
- X 1 is N; X 3 is CR 1 ; and X 5 is NR 1 , O or S; wherein each R 1 is as defined herein.
- X 1 is CR 1 ; X 3 is N; and X 5 is NR 1 , O or S; wherein each R 1 is as defined herein.
- X 1 is N; X 3 is N; and X 5 is NR 1 , O or S; wherein R 1 is as defined herein.
- the moiety has the structure of wherein each R 1 is as defined herein.
- the moiety has the structure of wherein each R 1 is as defined herein.
- the moiety has the structure of wherein each R 1 is as defined herein.
- the moiety has the structure of wherein each R 1 is as defined herein.
- the moiety has the structure of wherein each R 1 is as defined herein. In certain embodiments, the moiety has the structure of wherein each R 1 is as defined herein. In certain embodiments, the moiety has the structure of wherein each R 1 is as defined herein. In certain embodiments, the moiety has the structure of wherein each R 1 is as defined herein. In certain embodiments, the moiety has the structure of wherein each R 1 is as defined herein. In certain embodiments, the moiety has the structure of wherein each R 1 is as defined herein.
- the moiety has the structure of
- Cy is C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, or 5-10 membered heteroaryl.
- Cy is C 3 -C 10 cycloalkyl. In certain embodiments, Cy is saturated C 3 -C 10 cycloalkyl or partially unsaturated C 5 -C 10 cycloalkyl. In certain embodiments, Cy is saturated C 5 -C 7 cycloalkyl. In certain embodiments, Cy is unsaturated C 5 -C 7 cycloalkyl. In certain embodiments, Cy is cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, or cyclohexenyl.
- Cy is 4-10 membered heterocycloalkyl. In certain embodiments, Cy is saturated 4-10 membered heterocycloalkyl or partially unsaturated 5-10 membered heterocycloalkyl. In certain embodiments, Cy is saturated 5-7 membered heterocycloalkyl or partially unsaturated 5-7 membered heterocycloalkyl. In certain embodiments, each heterocycloalkyl has one or two heteroatoms, each of which is independently N, O, or S.
- Cy is C 6- C 10 aryl. In certain embodiments, Cy is phenyl or naphthyl. In certain embodiments, Cy is phenyl.
- Cy is 5-10 membered heteroaryl. In certain embodiments, Cy is monocyclic 5-10 membered heteroaryl. In certain embodiments, Cy is 6-membered heteroaryl. In certain embodiments, Cy is pyridinyl. In certain embodiments, Cy is 5-10 membered heteroaryl having one or two heteroatoms, each of which is independently N, O, or S. In certain embodiments, Cy is phenyl or 6-membered heteroaryl. In certain embodiments, Cy is phenyl or pyridinyl. In certain embodiments, Cy is phenyl or pyridin-4-yl.
- the moiety has the structure of wherein Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are each independently N or CR 2 ; and each R 2 is as defined herein.
- one of Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 is N; and the remaining four are each independently CR 2 , wherein R 2 is as defined herein.
- two of Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are N; and the remaining three are each independently CR 2 , wherein R 2 is as defined herein.
- Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are each independently CR 2 , wherein R 2 is as defined herein.
- the moiety has the structure of wherein each R 2 is as defined herein.
- the moiety has the structure of wherein each R 2 is as defined herein. In certain embodiments, the moiety has the structure of wherein each R 2 is as defined herein. In certain embodiments, the moiety has the structure of wherein each R 2 is as defined herein. In certain embodiments, the moiety has the structure of wherein each R 2 is as defined herein. In certain embodiments, the moiety has the structure of wherein each R 2 is as defined herein.
- the moiety has the structure of
- the moiety has the structure of
- each R 1 is independently H, D, –CN, –NO 2 , –N 3 , oxo, –SF 5 , halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, –NR C R D , –OR A , –SR A , –NR C OR A , –C (O) R B , –C (O) NR C R D , –C (O) OR A , –OC (O) R B , –NR C C (O) R B , –S (O) R B , –S (O) 2 R B , –S (O) NR C R D , –NR C S (O) 2 R D , –S
- each R 1 is independently selected from H, D, –CN, –NO 2 , –N 3 , oxo, –SF 5 , halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, –OR A , –SR A , –OC (O) R B , –OC (O) NR C R D , –NR C R D , –NR C C (O) R B , or –NR C C (O) OR A ; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A ;
- each R 1 is independently H, D, –CN, –NO 2 , –N 3 , oxo, –SF 5 , halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, –OR A , –SR A , –OC (O) R B , –OC (O) NR C R D , –NR C R D , –NR C C (O) R B , or –NR C C (O) OR A ; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A ; and each
- R 1 is H. In certain embodiments, R 1 is D. In certain embodiments, R 1 is –CN. In certain embodiments, R 1 is –NO 2 . In certain embodiments, R 1 is –N 3 . In certain embodiments, R 1 is –SF 5 . In certain embodiments, R 1 is halo. In certain embodiments, R 1 is –F, –Cl, –Br, or –I. In certain embodiments, R 1 is –F. In certain embodiments, R 1 is –Cl. In certain embodiments, R 1 is –Br. In certain embodiments, R 1 is –I.
- R 1 is –NR C R D , wherein R C and R D are each as defined herein.
- R 1 is –NH 2 , –NHCH 3 , –N (CH 3 ) 2 , –NHCH 2 CH 3 , –N (CH 2 CH 3 ) 2 , –NHCH 2 CH 2 CH 3 , –N (CH 2 CH 2 CH 3 ) 2 , –NHCH (CH 3 ) 2 , –NHCH 2 CH 2 OH, –N (CN) CH 3 ,
- R 1 is –OR A , wherein R A is as defined herein.
- R 1 is –OH, –OCH 3 , –OCH 2 CH 3 , –OCH 2 CH 2 CH 3 , –OCH (CH 3 ) 2 , –OCH 2 F, –OCHF 2 , –OCF 3 , –OCH 2 CH 2 OCHF 2 ,
- R 1 is –SR A , wherein R A is as defined herein. In certain embodiments, R 1 is –SCH 3 . In certain embodiments, R 1 is –NR C OR A , wherein R A and R C are each as defined herein. In certain embodiments, R 1 is –C (O) R B , wherein R B is as defined herein. In certain embodiments, R 1 is, –C (O) CH 3 , –C (O) CH 2 CH 3 , –C (O) CH (CH 3 ) 2 , or In certain embodiments, R 1 is –C (O) NR C R D , wherein R C and R D are each as defined herein.
- R 1 is –C (O) NH 2 , –C (O) NHCH 3 , or –C (O) N (CH 3 ) 2 .
- R 1 is –C (O) OR A , wherein R A is as defined herein.
- R 1 is -OC (O) R B , wherein R B is as defined herein.
- R 1 is –NR C C (O) R B , wherein R B and R C are each as defined herein.
- R 1 is –NHC (O) CH 3 , –NCH 3 C (O) CH 3 ,
- R 1 is C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- R 1 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, –CH 2 F, –CHF 2 , –CF 3 , –CH 2 CH 2 F, –CH 2 CHF 2 , –CH 2 CF 3 , –CD 3 , –CH 2 OH, –CH 2 OMe, –CH 2 CN,
- R 1 is methyl or –CD 3 .
- R 1 is methyl.
- R 1 is C 2 -C 6 alkenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein. In certain embodiments, R 1 is C 2 -C 6 alkynyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein. In certain embodiments, R 1 is
- R 1 is C 3 -C 10 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- R 1 is saturated C 3 -C 10 cycloalkyl or partially unsaturated C 3 -C 10 cycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- R 1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclopentadienyl, or cyclohexenyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- R 1 is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- R 1 is saturated 4-10 membered heterocycloalkyl or partially unsaturated 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- R 1 is azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, dioxanyl, piperazinyl, morpholinyl, 2, 6-diazaspiro [3.3] heptanyl, 2, 6-diazaspiro [3.3] heptanyl, 2-oxa-6-azaspiro [3.3] heptanyl, 7-oxa-4-azaspiro [2.5] octanyl, 3-azabicyclo [4.1.0] heptanyl, 3-azabicyclo [4.1.0] heptan-2-onyl, 4-oxa-7-azaspiro [2.5] octan-8-onyl, morpholin-3-onyl, piperazin-2-onyl, pyrrolidin-2-onyl, pyridin-2 (1H) -onyl, or 6, 7-dihydropyrazolo [
- R 1 is C 6 -C 10 aryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- R 1 is phenyl or naphthyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- R 1 is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- R 1 is pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, tetrazolyl, pyrazolyl, triazolyl, 1, 3, 4-thiadiazolyl, 1, 3, 4-oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, or isoindolyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- each R 1 is independently (i) H, D, –CN, or halo; or (ii) C 1 -C 6 alkyl or 5-10 membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- each R 1 is independently (i) H, D, or –CN; or (ii) C 1 -C 6 alkyl or 5-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- each R 1 is independently H, D, –CN, methyl, or 1-methyl-pyrazolyl.
- each R 1 is independently H or methyl.
- one of the R 1 groups is (i) –CN or halo; or (ii) C 1 -C 6 alkyl or 5-10 membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- one of the R 1 groups is –CN, methyl, or 1-methylpyrazolyl. In certain embodiments, one of the R 1 groups is methyl.
- one of the R 1 groups is (i) –CN or halo; or (ii) C 1 -C 6 alkyl or 5-10 membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 1A , wherein R 1A is as defined herein; and the remaining R 1 groups are each H.
- one of the R 1 groups is –CN, methyl, or 1-methylpyrazolyl; and the remaining R 1 groups are each H.
- one of the R 1 groups is methyl; and the remaining R 1 groups are each H.
- two R 1 together with the atom (s) to which they are attached form (i) oxo; or (ii) C 3 -C 7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, or 5-6 membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- two R 1 together with the same atom to which they are attached form oxo.
- two R 1 together with the atom (s) to which they are attached form C 3 -C 7 cycloalkyl optionally substituted by 1, 2, 3, or 4 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- two R 1 together with the atom (s) to which they are attached form cyclopropyl or cyclobutyl, each optionally substituted by 1, 2, 3, or 4 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- two R 1 together with the atom (s) to which they are attached form 4-7 membered heterocycloalkyl optionally substituted by 1, 2, 3, or 4 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- two R 1 together with the atoms to which they are attached form phenyl optionally substituted by 1, 2, 3, or 4 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- two R 1 together with the atoms to which they are attached form 5-6 membered heteroaryl ring optionally substituted by 1, 2, 3, or 4 substituents, each of which is independently R 1A , wherein R 1A is as defined herein.
- each R 1A is independently D, halo, –CN, –OH, –NH 2 , –NO 2 , –SF 5 , oxo, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, –NR c R d , –OR a , –SR a , –C (O) R b , –C (O) NR c R d , –C (O) OR a , –OC (O) R b , –OC (O) NR c R d , –NR c C (O) R b , –NR c C (O) NR c R d , –NR c C (O) OR a , –NR c C
- R 1A is D, halo, –CN, –OH, –NH 2 , –NO 2 , –SF 5 , or oxo.
- R 1A is D.
- R 1A is halo.
- R 1A is –F, –Cl, –Br, or –I.
- R 1A is –CN.
- R 1A is –OH.
- R 1A is –NH 2 .
- R 1A is –NO 2 .
- R 1A is –SF 5 .
- R 1A is oxo.
- R 1A is C 1 -C 4 alkyl optionally substituted with D, halo, –CN, –OH, –NH 2 , oxo, –NR c1 R d1 , –OR a1 , –SR a1 , C 1 -C 6 alkyl, or C 1- C 6 haloalkyl; wherein each R a1 , R c1 , and R d1 is as defined herein.
- R 1A is –CH 3 , –CH 2 CH 3 , –CH 2 CH 2 CH 3 , —CH (CH 3 ) 2 , –CH 2 CH 2 CH 2 CH 3 , –CH 2 CH (CH 3 ) 2 , –C (CH 3 ) 3 , –CH 2 F, –CHF 2 , –CF 3 , –CH 2 CH 2 F, –CH 2 CHF 2 , –CH 2 CF 3 , –CF 2 CH 3 , –CF 2 CF 3 , –CF 2 CH 2 CH 3 , —CH 2 OH, —CH 2 CH 2 OH, –CH (OH) CH 3 , –CH 2 CH 2 CH 2 OH, –CH (OH) CH 2 CH 2 OH, –CH 2 CN, –CH 2 CH 2 CN, or –CH 2 CH 2 CH 2 CN.
- R 2 is H, D, halo, –CN, –NO 2 , –N 3 , or –SF 5 .
- R 2 is H.
- R 2 is D.
- R 2 is halo.
- R 2 is–F, –Cl, –Br, or –I.
- R 2 is –F.
- R 2 is –Cl.
- R 2 is –Br.
- R 2 is –CN.
- R 2 is –NO 2 .
- R 2 is –N 3 .
- R 2 is –SF 5 .
- R 2 is–OR A , wherein R A is as defined herein.
- R 2 is –OCH 3 , –OCH 2 CH 3 , –OCH 2 CH 2 CH 3 , –OCH (CH 3 ) 2 , –OCH 2 F, –OCHF 2 , –OCF 3 , –OCH 2 CH 2 F, –OCH 2 CHF 2 , –OCF 2 CH 3 , –OCH 2 CF 3 , –OCH 2 CN, or –OCH 2 CONH 2 .
- R 2 is –SR A , wherein R A is as defined herein.
- R 2 is –SCH 3 .
- R 2 is –SCH 2 CH 3 .
- R 2 is –C (O) R B , wherein R B is as defined herein. In certain embodiments, R 2 is –C (O) NR C R D , wherein R C and R D are each as defined herein. In certain embodiments, R 2 is –C (O) OR A , wherein R A is as defined herein. In certain embodiments, R 2 is –OC (O) R B , wherein R B is as defined herein. In certain embodiments, R 2 is –NR C R D , wherein R C and R D are each as defined herein. In certain embodiments, R 2 is –NR C C (O) R B , wherein R B and R C are each as defined herein.
- R 2 is –S (O) R B , wherein R B is as defined herein. In certain embodiments, R 2 is –S (O) 2 R B , wherein R B is as defined herein. In certain embodiments, R 2 is –S (O) NR C R D , wherein R C and R D are each as defined herein. In certain embodiments, R 2 is – NR C S (O) 2 R D , wherein R C and R D are each as defined herein. In certain embodiments, R 2 is –S (O) 2 NR C R D , wherein R C and R D are each as defined herein.
- R 2 is –SiR G R H R I , wherein R G , R H , and R I are each as defined herein.
- R 2 is –B (OR E ) (OR F ) , wherein R E and R F are each as defined herein.
- R 2 is –P (O) R E R F , wherein R E and R F are each as defined herein.
- R 2 is –P (O) OR E OR F , wherein R E and R F are each as defined herein.
- R 2 is –OP (O) OR E OR F , wherein R E and R F are each as defined herein.
- R 2 is C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A , wherein R 2A is as defined herein.
- R 2 is C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, halo, –CN, –OH, –NH 2 , –NO 2 , –N 3 , oxo, –OC 1 -C 6 alkyl, –OC 1 -C 6 haloalkyl, –NHC 1 -C 3 alkyl, or –N (C 1- C 3 alkyl) 2 .
- R 2 is –CD 3 , –CH 3 , –CH 2 CH 3 , n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, –CH 2 F, –CHF 2 , –CF 3 , –CH 2 CH 2 F, –CH 2 CHF 2 , –CH 2 CF 3 , –CH 2 OH, –CH (OH) CH 3 , –CH 2 CH 2 OH, –CH 2 OCH 3 , –CH 2 OCHF 2 , –CH 2 OCH 2 F, –CH 2 OCF 3 , –CH (OCH 3 ) CH 3 , –CH 2 CH 2 NH 2 , –CH (NH 2 ) CH 3 , –CH 2 N (CH 3 ) 2 , –CH 2 CH 2 N (CH 3 ) 2 , or –CH 2 CN.
- R 2 is C 2 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, halo, –CN, –OH, –N 3 , –OC 1 -C 6 alkyl, C 1 -C 6 haloalkyl, –OC 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, or 4-6 membered heterocycloalkyl; wherein the cycloalkyl and heterocycloalkyl are each optionally substituted with D, halo, –CN, –OH, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, –O-C 1 -C 6 alkyl, or –O-C 1 -C 6 haloalkyl.
- R 2 is C 1 alkyl optionally substituted with 1, 2, or 3 substituents, each of which is independently D, halo, –CN, –OH, –N 3 , –OC 1 -C 6 alkyl, C 1 -C 6 haloalkyl, –OC 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, or 4-6 membered heterocycloalkyl; wherein the cycloalkyl and heterocycloalkyl are each optionally substituted with D, halo, –CN, –OH, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, –O-C 1 -C 6 alkyl, or –O-C 1 -C 6 haloalkyl.
- R 2 is C 2 -C 6 alkenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A , wherein R 2A is as defined herein.
- R 2 is C 2 -C 6 alkynyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A , wherein R 2A is as defined herein.
- R 2 is –C ⁇ CH or –C ⁇ CCH 3 .
- R 2 is C 3 -C 6 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A , wherein R 2A is as defined herein.
- R 2 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A , wherein R 2A is as defined herein.
- R 2 is 4-6 membered heterocycloalkyl having 1 or 2 heteroatoms, each independently selected from the group consisting of N, O, S, Si, and B, wherein each heteroatom is optionally substituted by one or more oxo, wherein the heterocycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A , and wherein R 2A is as defined herein.
- R 2 is azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, 1, 4-diazocanyl, 1, 4-diazepanyl, or azepanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A , wherein R 2A is as defined herein.
- R 2 is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A , wherein R 2A is as defined herein.
- R 2 is 5-6 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A , wherein R 2A is as defined herein.
- each R 2 is independently (i) H, D, halo, or –OR A ; or (ii) C 1 -C 6 alkyl, optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2A ; wherein R A and R 2A are each as defined herein.
- each R 2 is independently H, –F, –Cl, –CH 3 , –CF 3 , or –OCH 3 .
- one of the R 2 groups is –F. In certain embodiments, one of the R 2 groups is –Cl, –CH 3 , or –CF 3 . In certain embodiments, one of the R 2 groups is –OCH 3 .
- three of the R 2 groups are not H. In certain embodiments, three of the R 2 groups are not H; the first of the three is –F; the second of the three is –Cl, –CH 3 , or –CF 3 ; and the third of the three is –OCH 3 . In certain embodiments, three of the R 2 groups are not H; the first of the three is –F; the second of the three is –Cl; and the third of the three is –OCH 3 .
- each R 2A is independently D, halo, –CN, –OH, –NH 2 , –NO 2 , –N 3 , oxo, C 1 -C 6 alkyl, –OC 1 -C 6 alkyl, C 1 -C 6 haloalkyl, –OC 1 -C 6 haloalkyl, –NHC 1 -C 3 alkyl, –N (C 1 -C 3 alkyl) 2 , C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, or 4-6 membered heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl are each optionally substituted with D, halo, –CN, –OH, –NH 2 , C 1 -C 6 alkyl, C 1 -C 6 halo
- R 2A is D. In certain embodiments, R 2A is halo. In certain embodiments, R 2A is –F, –Cl, –Br, or –I. In certain embodiments, R 2A is –CN. In certain embodiments, R 2A is –OH. In certain embodiments, R 2A is –NH 2 . In certain embodiments, R 2A is –NO 2 . In certain embodiments, R 2A is –N 3 . In certain embodiments, R 2A is oxo.
- two R 2 when on adjacent ring vertices, together with the carbon atom (s) to which they are attached form C 4 -C 7 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 2B , wherein R 2B is as defined herein.
- two R 2 when on adjacent ring vertices, together with the carbon atom to which they are attached form 4-7 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4 or 5 substituents, each of which is independently R 2B , wherein R 2B is as defined herein.
- each R 2B is independently D, halo, oxo, –CN, –OH, –NH 2 , –NO 2 , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, –O-C 1 -C 6 alkyl, or –O-C 1 -C 6 haloalkyl.
- R 2B is D.
- R 2B is halo.
- R 2B is –F, –Cl, –Br, or –I.
- R 2B is oxo.
- R 2B is –CN.
- R 2B is –OH.
- R 2B is –NH 2 . In certain embodiments, R 2B is –NO 2 . In certain embodiments, R 2B is C 1 -C 6 alkyl. In certain embodiments, R 2B is C 1 -C 6 haloalkyl. In certain embodiments, R 2B is –O-C 1 -C 6 alkyl. In certain embodiments, R 2B is –O-C 1 -C 6 haloalkyl.
- each X 1 , X 2 , X 3 , and X 4 is independently N or CR 1 ;
- each X 5 is independently NR 1 , O or S;
- each Cy, R 1 , R 2 , R 3 , and m is as defined herein.
- Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are each independently N or CR 2 ; and ring A, R 1 , R 2 , R 3 , and n are each as defined herein.
- each ring A, R 1 , R 2 , R 3 , and n is as defined herein.
- R 3 is H, D, –CN, halo, –NO 2 , –N 3 , –SF 5 , –B (OR 5 ) (OR 6 ) , –SiR 5 R 6 R 7 , –SR 8 , –S (O) R 8 , –S (O) 2 R 8 , –NR 9 R 10 , –NR 9 C (O) R 8 , –C (O) R 8 , –S (O) NR 9 R 10 , –S (O) 2 NR 9 R 10 , C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl; wherein the alkyl, alkenyl, and alkynyl are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; wherein each R 4 , R 5 , R 6 , R 7 , R 8 , R 9
- R 3 is H, D, –CN, halo, –NO 2 , –N 3 , –SF 5 , –B (OR 5 ) (OR 6 ) , –SiR 5 R 6 R 7 , –SR 8 , –S (O) R 8 , –S (O) 2 R 8 , –NR 9 R 10 , –NR 9 C (O) R 8 , –C (O) R 8 , –S (O) NR 9 R 10 , or –S (O) 2 NR 9 R 10 , wherein each R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 is as defined herein.
- R 3 is –B (OR 5 ) (OR 6 ) , –SiR 5 R 6 R 7 , –SR 8 , –S (O) R 8 , –S (O) 2 R 8 , –NR 9 R 10 , –NR 9 C (O) R 8 , –C (O) R 8 , –S (O) NR 9 R 10 , or –S (O) 2 NR 9 R 10 , wherein each R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 is as defined herein.
- R 3 is –B (OR 5 ) (OR 6 ) , wherein R 5 and R 6 are each as defined herein.
- each R 5 and R 6 is independently H, D, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 7 cycloalkyl, 4-7 membered heterocycloalkyl, or phenyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, and phenyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, halo, –CN, –NO 2 , –N 3 , oxo, –NR C R D , –OR A , –SR A , –SiR G R H R I , –C (O) R B , –C (O) NR C R D , –OC (O) NR C R D , –NR C C (O) R B , –NR C C (O)
- R 3 is –SiR 5 R 6 R 7 , wherein R 5 , R 6 , and R 7 are each as defined herein.
- each R 5 , R 6 , and R 7 is independently H, D, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 7 cycloalkyl, 4-7 membered heterocycloalkyl, or phenyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, and phenyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, halo, –CN, –NO 2 , –N 3 , oxo, –NR C R D , –OR A , –SR A , –SiR G R H R I , –C (O) R B , –C (O) NR C R D , –OC (O) NR C R D , –NR C C (O) R B , –
- R 5 , R 6 , and R 7 are each independently C 1 -C 8 alkyl. In certain embodiments, R 5 , R 6 , and R 7 are each methyl.
- R 3 is –SR 8 , wherein R 8 is as defined herein.
- R 8 is C 1 -C 8 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is methyl, ethyl, propyl, butyl, pentyl, or hexyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, —CH 2 C (CH 3 ) 3 , –CH 2 F, –CHF 2 , –CF 3 , –CH 2 CH 2 F, –CH 2 CHF 2 , –CH 2 CF 3 , –CH 2 CN, –CH 2 CH 2 CN, –CH 2 CH 2 CH 2 CN, –CH (CH 3 ) CN, –C (CH 3 ) 2 CN, –CH 2 C (CH 3 ) 2 CN, –CH 2 CH 2 OH, –CH 2 CH 2 OCH 3 , –CH 2 CH 2 OCF 3 , –CH 2 CH 2 OCH 2 CH 3 , –CH 2 CH 2 CH 2 OH, –CH 2 CH 2 C (CH 3 ) 2 OH, –CH (CH 3 ) CH 2 CH 2 OH
- R 8 is C 2 -C 8 alkenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is C 2 -C 8 alkynyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is C 3 -C 10 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclopentadienyl, or cyclohexenyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein. In certain embodiments, R 8 is
- R 8 is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothio-phenyl, piperidinyl, dioxanyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, or morpholinyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is C 6 -C 10 aryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is phenyl or naphthyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, tetrazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, isoindolyl, indolizinyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzo [c] thiophenyl, indazolyl, benzo [d] imidazolyl, pyrrolo [3, 2-b] pyridinyl, pyrrol
- R 8 is C 1 -C 8 alkyl or C 3 -C 10 cycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 8A , wherein R 8A is as defined herein.
- R 8 is –CH 2 CH 3 , –CH 2 CF 3 , –CH 2 CH 2 OH, –CH 2 CH (CH 3 ) OH, –CH (CH 3 ) CH 2 OH, –CH 2 CH 2 OCH 3 , –CH 2 CH 2 CH 2 CN, –CH 2 CH 2 CH 2 OH, –CH 2 CH 2 C (CH 3 ) 2 OH, – CH (CH 3 ) CO 2 H, –CH (CH 3 ) CO 2 CH 2 CH 3 , –CH 2 CH 2 OSi (CH 3 ) 2 C (CH 3 ) 3 , or 2-hydroxycyclopentyl.
- R 3 is –S (O) R 8 , wherein R 8 is as defined herein.
- a compound of Formula (VIIa) , (VIIb) , (VIIc) , (VIId) , or (VIIe) is provided herein.
- R 3 is –S (O) 2 R 8 , wherein R 8 is as defined herein.
- R 3 is –NR 9 R 10 , wherein R 9 and R 10 are each as defined herein.
- R 9 is H. In certain embodiments, R 9 is D. In certain embodiments, R 9 is C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R
- R 9 is –CH 3 , –CH 2 CH 3 , –CH 2 CH 2 CH 3 , —CH (CH 3 ) 2 , –CH 2 CH 2 CH 2 CH 3 , –CH 2 CH (CH 3 ) 2 , or –C (CH 3 ) 3 .
- R 9 is C 3 -C 7 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b
- R 10 is H. In certain embodiments, R 10 is D. In certain embodiments, R 10 is C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR
- R 10 is –CH 3 , –CH 2 CH 3 , –CH 2 CH 2 CH 3 , —CH (CH 3 ) 2 , –CH 2 CH 2 CH 2 CH 3 , –CH 2 CH (CH 3 ) 2 , –C (CH 3 ) 3 , –CH 2 CF 3 , –CH 2 CH 2 OH, –CH 2 CH 2 OCH 3 , –CH 2 CH 2 OCH 2 CH 2 OH, –CH 2 CH 2 CN, –CH 2 CH 2 N (CH 3 ) C (O) CH 3 , –CH 2 CH 2 N (CH 3 ) S (O) 2 CH 3 , or –CH 2 CH 2 N (CH 3 ) S (O) 2 N (CH 3 ) 2 .
- R 10 is C 2 -C 6 alkenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2
- R 10 is C 2 -C 6 alkynyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, ––OC 1 -C 4 alkyl, OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O)
- R 10 is C 3 -C 7 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O)
- R 10 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , – –
- R 10 is 4-7 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2
- R 10 is azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, dioxanyl, tetrahydropyranyl, piperazinyl, or morpholinyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d ,
- R 10 is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d
- R 10 is 5-6 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR NR ,
- R 10 is pyrrolyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, 1, 2, 3-triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –
- R 10 is arylalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R
- R 10 is heteroarylalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R
- R 10 is cycloalkylalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR
- R 10 is heterocycloalkylalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR , –
- R 3 is –NR 9 C (O) R 8 , wherein R 8 and R 9 are each as defined herein. In certain embodiments, R 3 is –C (O) R 8 , wherein R 8 is as defined herein. In certain embodiments, R 3 is –S (O) NR 9 R 10 , wherein R 9 and R 10 are each as defined herein. In certain embodiments, R 3 is –S (O) 2 NR 9 R 10 , wherein R 9 and R 10 are each as defined herein.
- R 3 is C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 , wherein R 4 is as defined herein.
- each Y 3 , R 1 , R 2 , R 3 , and R 4 is as defined herein.
- Y 3 is CR 2 or N, wherein R 2 is as defined herein. In certain embodiments, Y 3 is CR 2 , wherein R 2 is as defined herein. In certain embodiments, Y 3 is CH. In certain embodiments, Y 3 is N.
- the moiety has the structure of
- the moiety has the structure of
- R 3 is C 1 -C 8 alkyl optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 , wherein R 4 is as defined herein.
- R 3 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, —CH 2 C (CH 3 ) 3 , –CH 2 F, –CHF 2 , –CF 3 , –CH 2 CH 2 F, –CH 2 CHF 2 , –CH 2 CF 3 , —CH (CH 3 ) F, –C (CH 3 ) 2 F, –CH 2 CH (CH 3 ) F, –CH 2 C (CH 3 ) 2 F, –CF 2 CH 3 , –CF 2 CH 2 CH 3 , –CF 2 CH (CH 3 ) 2 , –CF 2 CH (CH 3 ) 2 , –CF 2 CH (CH 3
- R 3 is straight-chained or branched C 1 -C 8 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; wherein one of R 4 is –OR A1 ; and wherein R 4 and R A1 are each as defined herein.
- R 3 is straight-chained or branched C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, each of which is independently R 4 ; wherein one of R 4 is –OR A1 ; and wherein R 4 and R A1 are each as defined herein.
- R 3 is wherein each R 4 and R A1 is as defined herein.
- each Y 3 , R 1 , R 2 , R 4 , R A1 , and m is as defined herein.
- Y 3 is CR 2 or N, wherein R 2 is as defined herein. In certain embodiments, Y 3 is CR 2 , wherein R 2 is as defined herein. In certain embodiments, Y 3 is CH. In certain embodiments, Y 3 is N.
- each R 4 is independently H, D, halo, –NO 2 , –N 3 , oxo, or C 1 -C 4 alkyl.
- one of R 4 is D.
- one of R 4 is halo.
- one of R 4 is –F, –Cl, –Br, or –I.
- one of R 4 is –F.
- two of R 4 are –F.
- one of R 4 is –CN.
- one of R 4 is –NO 2 .
- one of R 4 is –N 3 .
- two R 4 together with the carbon atom to which they are attached form oxo.
- one of R 4 is C 1 -C 4 alkyl.
- one of R 4 is methyl.
- R A1 is H. In certain embodiments, R A1 is D. In certain embodiments, R A1 is C 1 -C 8 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 11 , wherein R 11 is as defined herein. In certain embodiments, R A1 is methyl, ethyl, propyl, butyl, pentyl, or hexyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 11 , wherein R 11 is as defined herein.
- R A1 is H, D, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, —CH 2 C (CH 3 ) 3 , –CH 2 F, –CHF 2 , –CF 3 , –CH 2 CH 2 F, –CH 2 CHF 2 , –CH 2 CF 3 , –CH 2 CH 2 OH, –CH 2 CH (CH 3 ) OH, –CH 2 CH 2 OCH 3 , – CH 2 CH 2 OCH 2 CH 3 , –CH 2 CH 2 OCH 2 CH 2 OH, –CH 2 CH 2 OCH 2 CH 2 OCH 3 , –CH 2 CH 2 OCH 2 CH 2 OCH 3 , –CH 2 CH 2 OCH 2 CH 2 OCH 3 , –CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 3 , –CH 2 CH 2 SCH 3 , –CH 2 CH 2
- R A1 is C 2 -C 8 alkenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 11 , wherein R 11 is as defined herein.
- R A1 is C 2 -C 8 alkynyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 11 , wherein R 11 is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents independently selected from R 4 ; and one of R 4 is OR A2 ; wherein R 4 and R A2 are each as defined herein.
- R 3 is straight-chained or branched C 1 -C 3 alkyl optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from R 4 ; and one of R 4 is OR A2 ; wherein R 4 and R A2 are each as defined herein.
- R 3 is wherein each R 4 and R A2 is as defined herein.
- each Cy, R 1 , R 2 , R 4 , R A2 , and m is as defined herein, with the proviso that, when R A2 is C 6 -C 14 aryl or 5-14 membered heteroaryl, at least one of R 4 is not H.
- each R 4 is independently H, D, halo, –CN, –NO 2 , –N 3 , oxo, or C 1 -C 4 alkyl, with the proviso that, when R A2 is C 6 -C 14 aryl or 5-14 membered heteroaryl, at least one of R 4 is not H.
- one of R 4 is D. In certain embodiments, one of R 4 is halo. In certain embodiments, one of R 4 is –F, –Cl, –Br, or –I. In certain embodiments, one of R 4 is –F. In certain embodiments, two of R 4 are –F. In certain embodiments, one of R 4 is –CN. In certain embodiments, one of R 4 is –NO 2 . In certain embodiments, one of R 4 is –N 3 . In certain embodiments, two R 4 together with the carbon atom to which they are attached form oxo. In certain embodiments, one of R 4 is C 1 -C 4 alkyl. In certain embodiments, one of R 4 is methyl.
- R A2 is C 3 -C 14 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ; wherein R 12 is as defined herein.
- R A2 is saturated C 3 -C 14 cycloalkyl or partially unsaturated C 3 -C 14 cycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ; wherein R 12 is as defined herein.
- R A2 is cyclopropanyl, cyclobutenyl, cyclopentanyl, cyclohexanyl, cycloheptanyl, spiro [3.3] heptanyl, spiro [3.4] octanyl, spiro [3.5] nonanyl, spiro [3.6] decanyl, spiro [4.4] nonanyl, spiro [4.5] decanyl, spiro [4.6] undecanyl, spiro [5.6] dodecanyl, spiro [6.6] tridecanyl, bicyclo [2.2.0] hexanyl, bicyclo [3.2.0] heptanyl, bicyclo [4.2.0] octanyl, bicyclo [5.2.0] nonanyl, octahydropentalenyl, octahydro-1H-indenyl, decahydroazulenyl, decahydronaphth
- R A2 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ; wherein R 12 is as defined herein.
- R 3 is wherein each R 4 and R 12 is as defined herein.
- R A2 is saturated 4-14 membered heterocycloalkyl or partially unsaturated 4-14 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ; wherein R 12 is as defined herein.
- R A2 is azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-thiophenyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, 1, 4-diazocanyl, 1, 4-diazepanyl, azepanyl, 2, 6-diazaspiro [3.3] heptanyl, 2-oxa-6-azaspiro [3.3] heptanyl, 2, 6-diazaspiro [3.4] octanyl, 2, 7-diazaspiro [3.5] nonanyl, 2, 7-diazaspiro [4.4] nonanyl, 3, 9-diazaspiro-[5.5] undecanyl, 2-oxa-7-azaspiro [3.5] nonanyl, 2-oxa
- R A2 is azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, 1, 4-diazocanyl, 1, 4-diazepanyl, azepanyl, or 2, 6-diazaspiro [3.3] heptanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ; wherein R 12 is as defined herein.
- R 3 is wherein each R 4 and R 12 is as defined herein.
- at least one of R 4 is not H; and R A2 is C 6 -C 14 aryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ; wherein R 12 is as defined herein.
- at least one of R 4 is not H; and R A2 is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ; wherein R 12 is as defined herein.
- R 3 is wherein each R 4 and R 12 is as defined herein, with the proviso that at least one of R 4 is not H.
- R A2 is 5-14 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ; wherein R 12 is as defined herein; with the proviso that at least one of R 4 is not H.
- R A2 is pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, tetrazolyl, pyrazolyl, triazolyl, 1, 2, 4-triazolyl, 1, 2, 3-triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, isoindolyl, indolizinyl, benzofuranyl, isobenzofuranyl, benzo [b] thiophenyl, benzo [c] thiophenyl, indazolyl, benzo [d] imidazolyl, pyrrolo [3, 2-b] pyridinyl, pyrrolo [3, 2-c] pyridinyl, pyrrolo [2, 3-c] pyridinyl, pyrrolo [2,
- R A2 is pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, tetrazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 12 ; wherein R 12 is as defined herein; with the proviso that at least one of R 4 is not H.
- R 3 is
- each R 4 and R 12 is as defined herein; with the proviso that at least one of R 4 is not H.
- R 3 is straight-chained or branched C 1 -C 8 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –C (O) R B ; wherein R 4 and R B are each as defined herein.
- R 3 is straight-chained or branched C 1 -C 3 alkyl, optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –C (O) R B ; wherein R 4 and R B are each as defined herein.
- R 3 is wherein each R 4 and R B is as defined herein; with the proviso that one of R 4 is –C (O) R B .
- each R 4 is independently H, D, halo, –CN, NO 2 , –N 3 , oxo, or C 1 -C 4 alkyl, with the proviso that at least one of R 4 is not H; and each Cy, R 1 , R 2 , R B , and m is as defined herein.
- one of R 4 is D. In certain embodiments, one of R 4 is halo. In certain embodiments, one of R 4 is –F, –Cl, –Br, or –I. In certain embodiments, one of R 4 is –F. In certain embodiments, two of R 4 are –F. In certain embodiments, one of R 4 is –CN. In certain embodiments, one of R 4 is –NO 2 . In certain embodiments, one of R 4 is –N 3 . In certain embodiments, two R 4 together with the carbon atom to which they are attached form oxo. In certain embodiments, one of R 4 is C 1 -C 4 alkyl. In certain embodiments, one of R 4 is methyl.
- R B is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is methyl, ethyl, or propyl, each optionally substituted with 1, 2, 3, 4 or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is C 2 -C 6 alkenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is C 2 -C 6 alkynyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is C 3 -C 10 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or spiro [3.3] heptanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is saturated 4-10 membered heterocycloalkyl or partially unsaturated 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, dioxanyl, piperazinyl, morpholinyl, azepanyl, diazocanyl, 1, 4-diazepanyl, 4-oxa-7-azaspiro [2.5] -octanyl, 2, 6-diazaspiro [3.3] heptanyl, 2, 6-diazaspiro [3.4] octanyl, 2, 7-diazaspiro [3.5] nonanyl, 1, 8-diazaspiro [4.5] decanyl, octahydropyrrolo [3, 2-b] pyridinyl, hexahydropyrrolo [1, 2-a] imidazolyl, 2-oxa-5-azabicyclo [2.2.1] heptanyl, octahydropyrrolo [1, 2-a]
- R B is pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, 1, 4-diazepanyl, 4-oxa-7-azaspiro [2.5] octanyl, 1, 8-diazaspiro [4.5] decanyl, 2-oxa-5-azabicyclo [2.2.1] heptanyl, octahydropyrrolo [1, 2-a] pyrazinyl, hexahydropyrrolo- [1, 2-a] -pyrazinyl, 5, 6, 7, 8-tetrahydro [1, 2, 4] -triazolo [4, 3-a] pyrazinyl, or octahydropyrazino [2, 1-c] [1, 4] -oxazinyl, each optionally substituted with 1, 2, or 3 substituents, each of which is independently (i) cyano, –OR a , or –NR c R d ; or (
- R B is pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 1, 4-diazepan-1-yl, 4-oxa-7-azaspiro [2.5] octan-7-yl, 1, 8-diazaspiro [4.5] decan-8-yl, 2-oxa-5-azabicyclo [2.2.1] heptan-5-yl, octahydropyrrolo [1, 2-a] pyrazin-2-yl, hexahydropyrrolo- [1, 2-a] -pyrazin-2-yl, 5, 6, 7, 8-tetrahydro [1, 2, 4] triazolo [4, 3-a] pyrazin-7-yl, or octahydropyrazino [2, 1-c] [1, 4] -oxazin-8-yl, each optionally substituted with 1, 2, or 3 substituents, each of which is independently cyano
- R B is 3-hydroxypyrrolidin-1-yl, 3-methoxy-pyrrolidin-1-yl, 3- (dimethylamino) pyrrolidin-1-yl, 4-cyanopiperidin-1-yl, 3-hydroxypiperidin-1-yl, 4-hydroxy-piperidin-1-yl, 4-methoxypiperidin-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, 4-ethyl-piperazin-1-yl, 4- (2-hydroxyethyl) piperazin-1-yl, 4-methyl-1, 4-diazepan-1-yl, 4-oxa-7-azaspiro- [2.5] octan-7-yl, 1-ethyl-1, 8-diazaspiro [4.5] decan-8-yl, 2-oxa-5-azabicyclo [2.2.1] heptan-5-yl, octahydropyrrolo- [1, 2-a] pyrazin-2-yl
- R 3 is –CF 2 CH 2 COCH 3 , wherein each R B1 is as defined herein.
- R B is C 6 -C 10 aryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is pyrrolyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, 1, 2, 3-triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R B is arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein R B1 is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 , with the proviso that one of R 4 is –C (O) NR C R D ; wherein R 4 , R C , and R D are each as defined herein.
- R 3 is straight-chained or branched C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, each of which is independently R 4 , with the proviso that one of R 4 is –C (O) NR C R D ; wherein R 4 , R C , and R D are each as defined herein.
- R 3 is wherein each R 4 , R C , and R D is as defined herein.
- each R 4 is independently H, D, halo, –CN, –NO 2 , –N 3 , oxo, or C 1 -C 4 alkyl; with the proviso that at least one of R 4 is not H; and each Cy, R 1 , R 2 , R C , R D , and m are as defined herein.
- one of R 4 is D. In certain embodiments, one of R 4 is halo. In certain embodiments, one of R 4 is –F, –Cl, –Br, or –I. In certain embodiments, one of R 4 is –F. In certain embodiments, two of R 4 are –F. In certain embodiments, one of R 4 is –CN. In certain embodiments, one of R 4 is –NO 2 . In certain embodiments, one of R 4 is –N 3 . In certain embodiments, two R 4 together with the carbon atom to which they are attached form oxo. In certain embodiments, one of R 4 is C 1 -C 4 alkyl. In certain embodiments, one of R 4 is methyl.
- R C is (i) H, D, or –CN; or (ii) C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 6 -C 10 aryl-C 1 -C 6 alkyl, 5-10 membered heteroaryl-C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl-C 1 -C 6 alkyl, or 4-10 membered heterocycloalkyl-C 1 -C 6 alkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyano
- R C is H, D, C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d , –NR c S (O) 2
- R C is H, D, –CH 3 , –CH 2 CH 3 , –CH 2 CH 2 CH 3 , —CH (CH 3 ) 2 , –CH 2 CH 2 CH 2 CH 3 , –CH 2 CH (CH 3 ) 2 , or –C (CH 3 ) 3 .
- R C is (i) H; or (ii) C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 ,
- R C is (i) H; or (ii) C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, cycloalkylalkyl, or heteroarylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently cyano, halo, C 1 -C 4 alkyl, –OR a , or –NR c R d ; wherein each R a , R c , and R d is as defined herein.
- R C is (i) H; or (ii) methyl, ethyl, propyl, cyclopropyl, cyclohexyl, tetrahydropyranyl, pyrazolyl, cyclopropylmethyl, or pyridinyl-methyl, each optionally substituted with 1, 2, or 3, substituents, each of which is independently cyano, fluoro, methyl, hydroxyl, methoxy, or dimethylamino.
- R C is H, methyl, ethyl, 2-cyanoethyl, 2, 2, 2-trifluoroethyl, 2-hydroxyethyl, 2-methoxyethyl, 2-dimethylaminoethyl, isopropyl, 2-hydroxypropyl, 2-hydroxy-2-methylpropyl, 2-methoxy-2-methylpropyl, cyclopropyl, 4-hydroxy-cyclohexyl, tetrahydropyran-4-yl, 1-methylpyrazol-4-yl, (1-hydroxycyclopropyl) methyl, (1-methoxycyclopropyl) methyl, or pyridin-2-ylmethyl.
- R C is H, methyl, or ethyl.
- R D is independently (i) H, D, or –CN; or (ii) C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 6 -C 10 aryl-C 1 -C 6 alkyl, 5-10 membered heteroaryl-C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl-C 1 -C 6 alkyl, or 4-10 membered heterocycloalkyl-C 1 -C 6 alkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyan
- R D is H. In certain embodiments, R D is D. In certain embodiments, R D is C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O)
- R D is –CH 3 , –CH 2 CH 3 , –CH 2 CH 2 CH 3 , —CH (CH 3 ) 2 , –CH 2 CH 2 CH 2 CH 3 , –CH 2 CH (CH 3 ) 2 , –C (CH 3 ) 3 , –CH 2 CF 3 , –CH 2 CH 2 OH, –CH 2 CH 2 OCH 3 , –CH (CH 3 ) CH 2 OH, –CH (CH 3 ) CH 2 OCH 3 , –CH 2 CH (CH 3 ) OH, –CH 2 CH (CH 3 ) OCH 3 , –CH 2 C (CH 3 ) 2 OH, –CH 2 C (CH 3 ) 2 OCH 3 , –CH 2 CH 2 NH 2 , –CH 2 CH 2 NH (CH 3 ) , –CH 2 CH 2 N (CH 3 ) 2 , –CH 2 CH 2 CN, –CH 2 CH 2 N (CH 3 ) 3 ,
- R D is C 2 -C 6 alkenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d , –NR c S (O) 2 R b
- R D is C 2 -C 6 alkynyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d , –NR c S (O) 2 R
- R D is C 3 -C 10 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d , –NR c S (O) 2 R
- R D is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) (O
- R D is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d , – NR c S (O) 2 R
- R D is azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, dioxanyl, tetrahydropyranyl, piperazinyl, morpholinyl, azepanyl, diazocanyl, 1, 4-diazepanyl, 2, 6-diazaspiro [3.3] heptanyl, 6-diazaspiro [3.4] octanyl, or 2, 7-diazaspiro [3.5] nonanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-
- R D is C 6 -C 10 aryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d , –NR c S (O) 2 b ,
- R D is phenyl or naphthyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d , –NR c S (O) 2 R
- R D is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d , –NR c S (O) 2 b ,
- R D is pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, tetrazolyl, pyrazolyl, 1, 2, 4-triazolyl, 1, 2, 3-triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, isoindolyl, indolizinyl, benzofuranyl, or isobenzofuranyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-
- R D is C 6 -C 10 aryl-C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d ,
- R D is benzyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d , –NR c S (O) 2 NR c R d ,
- R D is 5-10 membered heteroaryl-C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d ,
- R D is –CH 2 -pyrrolyl, –CH 2 -imidazolyl, –CH 2 -oxazolyl, –CH 2 -isoxazolyl, –CH 2 -thiazolyl, –CH 2 -tetrazolyl, –CH 2 -pyrazolyl, –CH 2 -1, 2, 4-triazolyl, –CH 2 -1, 2, 3-triazolyl, –CH 2 -thiadiazolyl, –CH 2 -oxadiazolyl, –CH 2 -pyridinyl, –CH 2 -pyrimidinyl, –CH 2 -pyrazinyl, –CH 2 -pyridazinyl, –CH 2 -indolyl, or –CH 2 -isoindolyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, ox
- R D is C 3 -C 10 cycloalkyl-C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R
- R D is –CH 2 -cyclopropyl, –CH 2 -cyclobutyl, –CH 2 -cyclopentyl, or –CH 2 -cyclohexyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b
- R D is 4-10 membered heterocycloalkyl-C 1 -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 , –OR a , –OC (O) NR c R d , –NR c R d , –NR c C (O) R b , –S (O) NR c R d , –S (O) 2 R b , –NR c S (O) 2 R b , –S (O) 2 NR c R d
- R D is –CH 2 -azetidinyl, –CH 2 -oxetanyl, –CH 2 -pyrrolidinyl, –CH 2 -tetrahydrofuranyl, –CH 2 -piperidinyl, –CH 2 -dioxanyl, –CH 2 -tetrahydropyranyl, –CH 2 -piperazinyl, –CH 2 -morpholinyl, –CH 2 -azepanyl, –CH 2 -diazocanyl, –CH 2 -1, 4-diazepanyl, or –CH 2 -azepanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 —CN,
- R D is (i) H; or (ii) C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 haloalkyl, –SF 5 ,
- R D is (i) H; or (ii) C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, cycloalkylalkyl, or heteroarylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently cyano, halo, C 1 -C 4 alkyl, –OR a , or –NR c R d ; wherein each R a , R c , and R d is as defined herein.
- R D is (i) H; or (ii) methyl, ethyl, propyl, cyclopropyl, cyclohexyl, tetrahydropyranyl, pyrazolyl, cyclopropylmethyl, or pyridinyl-methyl, each optionally substituted with 1, 2, or 3, substituents, each of which is independently cyano, fluoro, methyl, hydroxyl, methoxy, or dimethylamino.
- R D is H, methyl, ethyl, 2-cyanoethyl, 2, 2, 2-trifluoroethyl, 2-hydroxyethyl, 2-methoxyethyl, 2-dimethylaminoethyl, isopropyl, 2-hydroxypropyl, 2-hydroxy-2-methylpropyl, 2-methoxy-2-methylpropyl, cyclopropyl, 4-hydroxy-cyclohexyl, tetrahydropyran-4-yl, 1-methylpyrazol-4-yl, (1-hydroxycyclopropyl) methyl, (1-methoxycyclopropyl) methyl, or pyridin-2-ylmethyl.
- R 3 is –CF 2 CH 2 CONHCH 3 , –CF 2 CH 2 CON (CH 3 ) 2 ,
- R 3 is straight-chained or branched C 1 -C 8 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –C (O) OR A ; wherein R 4 and R A are each as defined herein.
- R 3 is straight-chained or branched C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –C (O) OR A ; wherein R 4 and R A are each as defined herein.
- R 3 is wherein each R 4 and R A is as defined herein.
- R 3 is
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –C (O) NR C S (O) R B ; wherein R 4 , R B , and R C are each as defined herein.
- R 3 is wherein each R 4 , R B , and R C is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –C (O) NR C S (O 2 ) R B ; wherein R 4 , R B , and R C are each as defined herein.
- R 3 is wherein each R 4 , R B , and R C is as defined herein.
- R 3 is
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –OC (O) R B ; wherein R 4 and R B are each as defined herein. In certain embodiments, R 3 is wherein each R 4 and R B is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –OC (O) NR C R D ; wherein R 4 , R C , and R D are each as defined herein. In certain embodiments, R 3 is wherein each R 4 , R C , and R D is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –NR C R D ; wherein R 4 , R C , and R D are each as defined herein. In certain embodiments, R 3 is wherein each R 4 , R C , and R D is as defined herein.
- R 3 is, –CF 2 CH 2 NH 2 , –CF 2 CH 2 NHCH 3 , –CF 2 CH 2 N (CH 3 ) 2 , –CF 2 CH 2 NHCH 2 CH 3 , –CF 2 CH 2 N (CH 2 CH 3 ) 2 , –CF 2 CH 2 CH 2 NH 2 , –CF 2 CH 2 CH 2 NHCH 3 , –CF 2 CH 2 CH 2 N (CH 3 ) 2 , –CF 2 CH 2 CH 2 NHCH 2 CH 3 , or –CF 2 CH 2 CH 2 N (CH 2 CH 3 ) 2 .
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –NR C C (O) R B ; wherein R 4 , R B , and R C are each as defined herein. In certain embodiments, R 3 is wherein each R 4 , R B , and R C is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –NR C C (O) NR C R D ; wherein each R 4 , R C , and R D is as defined herein. In certain embodiments, R 3 is wherein each R 4 , R C , and R D is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –NR C C (O) OR A ; wherein R 4 , R A , and R C are each as defined herein. In certain embodiments, R 3 is wherein each R 4 , R A , and R C is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –SR A ; wherein R 4 and R A are each as defined herein. In certain embodiments, R 3 is wherein each R 4 and R A is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –S (O) R B ; wherein R 4 and R B are each as defined herein. In certain embodiments, R 3 is wherein each R 4 and R B is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –S (O) 2 R B ; wherein R 4 and R B are each as defined herein. In certain embodiments, R 3 is wherein each R 4 and R B is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –S (O) NR C R D ; wherein R 4 , R C , and R D are each as defined herein. In certain embodiments, R 3 is wherein each R 4 , R C , and R D is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –NR C S (O) 2 R D ; wherein R 4 , R C , and R D are each as defined herein. In certain embodiments, R 3 is wherein each R 4 , R C , and R D is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –S (O) 2 NR C R D ; wherein R 4 , R C , and R D are each as defined herein.
- R 3 is wherein each R 4 , R C , and R D is as defined herein.
- R 3 is straight-chained or branched C 1 -C 8 alkyl or C 1 -C 3 alkyl, each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; with the proviso that one of R 4 is –NR C S (O) 2 NR C R D ; wherein each R 4 , R C , and R D is as defined herein. In certain embodiments, R 3 is wherein each R 4 , R C , and R D is as defined herein.
- R 3 is C 2 -C 8 alkenyl optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; wherein R 4 is as defined herein.
- R 3 is C 2 -C 8 alkynyl optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents, each of which is independently R 4 ; wherein R 4 is as defined herein.
- R 3 is C 6 -C 10 aryl, C 3 -C 10 cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 3 is C 6 -C 10 aryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 3 is phenyl or naphthyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 3 is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 3 is C 3 -C 10 cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 3 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 3 is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 3 is pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, tetrazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 3 is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 3 is azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, 1, 4-diazocanyl, 1, 4-diazepanyl, azepanyl, or 2, 6-diazaspiro [3.3] heptanyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R 13 ; wherein R 13 is as defined herein.
- R 13 is H. In certain embodiments, R 13 is D. In certain embodiments, R 13 is halo. In certain embodiments, R 13 is –F, –Cl, –Br, or –I. In certain embodiments, R 13 is –SF 5 . In certain embodiments, R 13 is –CN. In certain embodiments, R 13 is –NO 2 . In certain embodiments, R 13 is oxo.
- R 13 is C 1 -C 6 alkyl. In certain embodiments, R 13 is –CH 3 , –CH 2 CH 3 , –CH 2 CH 2 CH 3 , —CH (CH 3 ) 2 , –CH 2 CH 2 CH 2 CH 3 , –CH 2 CH (CH 3 ) 2 , or –C (CH 3 ) 3 . In certain embodiments, R 13 is C 2 -C 6 alkenyl. In certain embodiments, R 13 is C 2 -C 6 alkynyl. In certain embodiments, R 13 is C 1 -C 6 haloalkyl.
- R 13 is –CH 2 F, –CHF 2 , –CF 3 , –CH 2 CH 2 F, –CH 2 CHF 2 , –CH 2 CF 3 , –CF 2 CH 3 , or –CF 2 CH 2 CH 3 .
- R 13 is C 1 -C 6 cyanoalkyl.
- R 13 is –CH 2 CN, –CH 2 CH 2 CN, or –CH 2 CH 2 CH 2 CN.
- R 13 is –SR A , wherein R A is as defined herein. In certain embodiments, R 13 is –OR A , wherein R A is as defined herein. In certain embodiments, R 13 is –OCH 3 , –OCH 2 CH 3 , –OCH 2 CH 2 CH 3 , –OCH (CH 3 ) 2 , –OCH 2 F, –OCHF 2 , –OCF 3 , –OCH 2 CH 2 F, –OCH 2 CHF 2 , or –OCH 2 CF 3 .
- R 13 is –C (O) R B , wherein R B is as defined herein. In certain embodiments, R 13 is –C (O) NR C R D , wherein R C and R D are each as defined herein. In certain embodiments, R 13 is –C (O) OR A , wherein R A is as defined herein. In certain embodiments, R 13 is –OC (O) R B , wherein R B is as defined herein. In certain embodiments, R 13 is –OC (O) NR C R D , wherein R C and R D are each as defined herein.
- R 13 is –NR C R D , wherein R C and R D are each as defined herein.
- R 13 is –NR C C (O) R B , wherein R B and R C are each as defined herein.
- R 13 is –NR C C (O) NR C R D , wherein each R C and R D is as defined herein.
- R 13 is –NR C C (O) OR A , wherein R A and R C are each as defined herein.
- R 13 is –SiR G R H R I , wherein R G , R H , and R I are each as defined herein.
- R 13 is –B (OR E ) (OR F ) , wherein R E and R F are each as defined herein.
- R 13 is –S (O) R B , wherein R B is as defined herein.
- R 13 is –S (O) NR C R D , wherein R C and R D are each as defined herein.
- XVa a compound of Formula (XVa) , (XVb) , (XVc) , (XVd) , or (XVe) :
- each Y 3 , R 1 , R 2 , and R 3 is as defined herein.
- each Y 3 , R 1 , R 2 , and R 3 is as defined herein.
- XVIIa a compound of Formula (XVIIa) , (XVIIb) , (XVIIc) , (XVIId) , or (XVIIe) :
- each Y 3 , R 1 , R 2 , and R 3 is as defined herein.
- R A is H or D.
- R A is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which independently selected from D, –OH, –CN, halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkyl-OH, C 1 -C 4 alkyl-CN, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1
- R B is H or D.
- R B is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently R B1 ; wherein each R B1 is independently D, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkyl-O-C 1 -C 4 alkyl, C 1 -C 4 alkyl-O-C 1 -C 1 -
- R C and R D are each independently H, D, or –CN.
- R C and R D are each independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, each optionally substituted with 1, 2, 3, 4 or 5 substituents, each of which is independently D, –OH, –CN, halo, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, –OC 1 -C 4 haloalkyl, C 1 -C 4 alkyl-
- R C and R D together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, oxo, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1 -C 4 alkyl) 2 , halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 cyanoalkyl, –OC 1 -C 4 alkyl, or –OC 1 -C 4 haloalkyl.
- R a is H or D.
- R a is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, phenyl, C 3 -C 7 cycloalkyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, halo, –OH, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1 -C 4 alkyl) 2 , C 1 -C 4 alkyl, –OC 1 -C 4 alkyl, C 1 -C 4 haloalkyl, or –OC 1 -C 4 haloalkyl.
- R a1 is H or D.
- R a1 is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, phenyl, C 3 -C 7 cycloalkyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, halo, –OH, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1 -C 4 alkyl) 2 , C 1 -C 4 alkyl, –OC 1 -C 4 alkyl, C 1 -C 4 haloalkyl, or –OC 1 -C 4 haloalkyl.
- R b is H or D.
- R b is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, phenyl, C 3- C 7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1 -C 4 alkyl) 2 , halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 6- C 10 aryl,
- R b1 is H or D.
- R b1 is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, phenyl, C 3- C 7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is Independently D, –OH, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1 -C 4 alkyl) 2 , halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 6- C 10
- R c and R d are each independently H or D.
- R c and R d are each independently C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 6- C 10 aryl, 5-10 membered heteroaryl, C 3- C 10 cycloalkyl, 4-10 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl, or biheteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, –
- R c and R d together with the N atom to which they are attached form 4-7 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is independently D, –OH, –CN, –NH 2 , –NH (C 1 -C 4 alkyl) , –N (C 1 -C 4 alkyl) 2 , halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 4 hydroxyalkyl, C 1 -C 4 cyanoalkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 1 -C 4 alkoxy-C 1 -C 4 alkyl, or C 1 -C 4 alkoxy-C 1 -C 4 alkoxy.
- R E is H or D.
- R E is C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, (C 1 -C 4 alkoxy) -C 1 -C 4 alkyl, C 2 -C 4 alkynyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl-C 1 -C 4 alkyl, C 3 -C 10 cycloalkyl-C 1 -C 4 alkyl, 5-10 membered heteroaryl-C 1 -C 4 alkyl, or 4-10 membered heterocycloalkyl-C 1 -C 4 alkyl.
- R F is H or D. In certain embodiments, R F is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 3 -C 10 cycloalkyl, or 4-10 membered heterocycloalkyl.
- R e is C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, (C 1 -C 4 alkoxy) -C 1 -C 4 alkyl, C 2 -C 4 alkynyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 3 -C 10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -C 10 aryl-C 1 -C 4 alkyl, C 3 -C 10 cycloalkyl-C 1 -C 4 alkyl, 5-10 membered heteroaryl-C 1 -C 4 alkyl, or 4-10 membered heterocycloalkyl-C 1 -C 4 alkyl.
- R f is H or D. In certain embodiments, R f is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, C 3 -C 10 cycloalkyl, or 4-10 membered heterocycloalkyl.
- R G , R H and R I are each independently C 1 -C 4 alkyl or phenyl. In certain embodiments, R G is C 1 -C 4 alkyl or phenyl. In certain embodiments, R G is C 1 alkyl, C 2 alkyl, C 3 alkyl, or C 4 alkyl. In certain embodiments, R G is methyl, ethyl, propyl, butyl, or phenyl. In certain embodiments, R G is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, or phenyl.
- R H is C 1 -C 4 alkyl or phenyl. In certain embodiments, R H is C 1 alkyl, C 2 alkyl, C 3 alkyl, or C 4 alkyl. In certain embodiments, R H is methyl, ethyl, propyl, butyl, or phenyl. In certain embodiments, R H is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, or phenyl. In certain embodiments, R I is C 1 -C 4 alkyl or phenyl.
- R I is C 1 alkyl, C 2 alkyl, C 3 alkyl, or C 4 alkyl. In certain embodiments, R I is methyl, ethyl, propyl, butyl, or phenyl. In certain embodiments, R I is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, or phenyl.
- R g , R h and R i are each independently C 1 -C 4 alkyl or phenyl. In certain embodiments, R g is C 1 -C 4 alkyl or phenyl. In certain embodiments, R g is C 1 alkyl, C 2 alkyl, C 3 alkyl, or C 4 alkyl. In certain embodiments, R g is methyl, ethyl, propyl, butyl, or phenyl. In certain embodiments, R g is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, or phenyl.
- R h is C 1 -C 4 alkyl or phenyl. In certain embodiments, R h is C 1 alkyl, C 2 alkyl, C 3 alkyl, or C 4 alkyl. In certain embodiments, R h is methyl, ethyl, propyl, butyl, or phenyl. In certain embodiments, R h is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, or phenyl. In certain embodiments, R i is C 1 -C 4 alkyl or phenyl.
- R i is C 1 alkyl, C 2 alkyl, C 3 alkyl, or C 4 alkyl. In certain embodiments, R i is methyl, ethyl, propyl, butyl, or phenyl. In certain embodiments, R i is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, or phenyl.
- provided herein is a compound of:
- the compounds provided herein can be asymmetric (e.g., having one or more stereocenters) . All stereoisomers, such as enantiomers and diastereomers, are contemplated unless otherwise indicated.
- Cis and trans geometric isomers of the compounds provided herein are described and may be isolated as a mixture of isomers or as separated isomeric forms. Furthermore, atropisomers and mixtures thereof such as those resulting from restricted rotation about two aromatic or heteroaromatic rings bonded to one another are encompassed within the scope of the disclosure.
- the compounds provided herein also include tautomeric forms.
- Prototropic tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
- Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
- prototropic tautomers examples include ketone–enol pairs, amide-imidic acid pairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H-and 3H-imidazole, 1H-, 2H-, and 4H-1, 2, 4-triazole, 1H-and 2H-isoindole, and 1H-and 2H-pyrazole; certain hydroxy substituted compounds may exist as tautomers as shown below: etc. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- the compounds of the present disclosure may exist as rotational isomers. Descriptions of a compound of the disclosure that do not indicate a particular rotational isomer are intended to encompass any individual rotational isomers, as well as mixtures of rotational isomers in any proportion. Depiction of a particular rotational isomer is meant to refer to the depicted rotational isomer, substantially free of other rotational isomers.
- Compounds of the disclosure can also include all isotopes of atoms occurring in the intermediates or final compounds.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium.
- the present disclosure also includes pharmaceutically acceptable salts of the compounds provided herein.
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids.
- the pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. Lists of suitable salts are found in Remington’s Pharmaceutical Sciences, 17 th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and J. Pharm. Sci. 1977, 66, 2, each of which is incorporated herein by reference in its entirety.
- a pharmaceutical composition comprising a compound provided herein, e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; and a pharmaceutically acceptable excipient.
- compositions can be formulated in a form suitable for oral administration (for example, as tablets, lozenges, hard or soft capsules, aqueous or oil suspensions, emulsions, dispersible powders or granules, syrups, or elixirs) , for injection (for example, as aqueous or oil suspensions, emulsions, elixirs, or a sterile aqueous solution) , for topical application (for example, as creams, ointments, gels, or aqueous or oil solutions or suspensions) , for inhalation (for example, as a finely divided powder or a liquid aerosol) , for insufflation (for example, as a finely divided powder) , or for parenteral administration (for example, as a sterile aqueous or oil solution for intravenous, subcutaneous, intramuscular, intraperitoneal, or intramuscular dosing, or as a suppository for rectal dos
- the pharmaceutically acceptable excipient (s) can be, for example, carriers (e.g., a solid, liquid, or semi-solid carrier) , adjuvants, diluents, fillers or bulking agents, granulating agents, coating agents, release-controlling agents, binding agents, disintegrants, lubricating agents, preservatives, antioxidants, buffering agents, suspending agents, thickening agents, flavoring agents, sweeteners, taste masking agents, or stabilizers.
- carriers e.g., a solid, liquid, or semi-solid carrier
- adjuvants e.g., a solid, liquid, or semi-solid carrier
- granulating agents e.g., granulating agents, coating agents, release-controlling agents, binding agents, disintegrants, lubricating agents, preservatives, antioxidants, buffering agents, suspending agents, thickening agents, flavoring agents, sweeteners, taste masking agents, or stabilizers.
- the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
- solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
- liquid carriers include sugar syrup, peanut oil, olive oil, and water.
- gaseous carriers include carbon dioxide and nitrogen.
- water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents may be used to form oral solid preparations, such as powders, capsules, and tablets.
- Pharmaceutical dosage forms suitable for oral administration include tablets (coated or uncoated) , capsules (hard or soft shell) , caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs, suspensions, sublingual tablets, wafers, or patches such as buccal patches.
- tablet compositions can contain a unit dosage of an active compound together with an inert diluent or carrier such as a sugar or sugar alcohol, e.g., lactose, sucrose, sorbitol or mannitol; and/or a non-sugar derived diluent such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or derivative thereof, such as microcrystalline cellulose (MCC) , methyl cellulose, ethyl cellulose, and hydroxypropyl methyl cellulose, and starches such as corn starch.
- an inert diluent or carrier such as a sugar or sugar alcohol, e.g., lactose, sucrose, sorbitol or mannitol
- a non-sugar derived diluent such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or derivative thereof, such as microcrystalline cellulose (MCC) , methyl cellulose, eth
- Tablets may also contain such standard ingredients as binding and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g., swellable crosslinked polymers such as crosslinked carboxymethylcellulose) , lubricating agents (e.g., stearates) , preservatives (e.g., parabens) , antioxidants (e.g., BHT) , buffering agents (for example phosphate or citrate buffers) , and effervescent agents such as citrate/bicarbonate mixtures.
- binding and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g., swellable crosslinked polymers such as crosslinked carboxymethylcellulose) , lubricating agents (e.g., stearates) , preservatives (e.g., parabens) , antioxidants (e.g., BHT) , buffering agents (for example phosphate or citrate buffers)
- compositions of the present disclosure suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
- a suitable surfactant can be included such as, for example, hydroxypropyl cellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
- compositions of the present disclosure suitable for injectable use include sterile aqueous solutions or dispersions.
- the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
- the final injectable form must be sterile and must be effectively fluid for easy syringability.
- the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
- compositions of the present disclosure can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, or dusting powder. Further, the compositions can be in a form suitable for use in transdermal devices.
- the pharmaceutical formulations described herein may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including antioxidants) .
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including antioxidants) .
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including antioxidants) .
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including antioxidants) .
- preservatives including antioxidants
- provided herein is a method for treating or preventing cancer in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a compound provided herein e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- the cancer is characterized by PolQ overexpression. In certain embodiments, the cancer is the characterized by increased dependence on MMEJ DSB repair. In certain embodiments, the cancer is characterized by HR-deficiency. In certain embodiments, the cancer is characterized by a reduction or absence of expression of a HR-associated gene. In certain embodiments, the cancer lacks a 53BP1/Shieldin complex. In certain embodiments, the cancer is resistant to PARPi treatment. In certain embodiments, the cancer is characterized by NHEJ deficiency. In certain embodiments, the cancer is a reduction or absence of expression of an NHEJ-associated gene.
- a method for treating or preventing a disease characterized by PolQ overexpression in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a compound provided herein e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- PolQ overexpression refers to the increased expression or activity of a PolQ enzyme in a diseased cell, e.g., cancer cell, relative to the expression or activity of a PolQ enzyme in a control cell (e.g., non-diseased cell of the same type) .
- the PolQ overexpression is at least 2-fold, at least 3-fold, at least 4-fold, at least 6-fold, at least 10-fold, at least 20-fold, or at least 50-fold relative to the PolQ expression in a control cell.
- PolQ overexpressing cancer include, but are not limited to, certain ovarian, breast, cervical, uterine, pancreatic, lung, colorectal, gastric, bladder, and prostate cancer.
- a method for treating or preventing a disease characterized by increased dependence upon MMEJ DSB repair in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a compound provided herein e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a method for treating or preventing a disease characterized by HR-deficiency, a reduction or absence of the expression of an HR-associated gene in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a compound provided herein e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- the HR-associated gene is ATM, ATR, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, CtIP (BCL11A) , ERCC4 (FANCQ) , FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANJ (BRIP1) , FANCL, FANCM, FANCN (PALB2) , FANCP (SLX4) , LIG1, MRE11, NBS1, NBN, PTEN, RAD50, RAD51B, RAD51C, RAD54, RECQL4, RPA1, RPA2, SMARCA2, SMARCA4, WRN, or XRCC2.
- a method for treating or preventing a disease lacking a 53BP1/Shieldin complex in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a compound provided herein e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a method for treating or preventing a disease resistant to PARPi treatment in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a compound provided herein e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a method for treating or preventing a disease characterized by NHEJ deficiency, or a reduction or absence of expression of an NHEJ-associated gene in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- a compound provided herein e.g., a compound of Formula (I) , or a pharmaceutically acceptable salt, solvate, N-oxide, tautomer, stereoisomer, atropisomer, isotopic variant, prodrug, or deuterated compound thereof; or a pharmaceutical composition provided herein.
- the NHEJ-associated gene is 53BP1, DCLRE1C, LIG4, NHEJ1, POLL, POLM, PRKDC, RIF1, SHLD1, SHLD2, SHLD3, XRCC4, XRCC5, or XRCC6.
- the subject is a mammal. In certain embodiments, the subject is a human.
- the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 100 mg/kg/day, from about 0.1 to about 50 mg/kg/day, from about 0.1 to about 25 mg/kg/day, from about 0.1 to about 20 mg/kg/day, from about 0.1 to about 15 mg/kg/day, from about 0.1 to about 10 mg/kg/day, or from about 0.1 to about 5 mg/kg/day.
- the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 100 mg/kg/day.
- the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 50 mg/kg/day.
- the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 25 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 20 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 15 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 10 mg/kg/day. In still another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 5 mg/kg/day.
- the administered dose can also be expressed in units other than mg/kg/day.
- doses for parenteral administration can be expressed as mg/m 2 /day.
- doses for parenteral administration can be expressed as mg/m 2 /day.
- One of ordinary skill in the art would readily know how to convert doses from mg/kg/day to mg/m 2 /day to given either the height or weight of a subject or both. For example, a dose of 1 mg/m 2 /day for a 65 kg human is approximately equal to 58 mg/kg/day.
- a compound provided herein may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, CIV, intracisternal injection or infusion, subcutaneous injection, or implant) , inhalation, nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration.
- parenteral e.g., intramuscular, intraperitoneal, intravenous, CIV, intracisternal injection or infusion, subcutaneous injection, or implant
- inhalation nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration.
- a compound provided herein may be formulated in suitable dosage unit with a pharmaceutically acceptable excipient, carrier, adjuvant, or vehicle, appropriate for each route of administration.
- a compound provided herein is administered orally. In another embodiment, a compound provided herein is administered parenterally. In yet another embodiment, a compound provided herein is administered intravenously. In yet another embodiment, a compound provided herein is administered intramuscularly. In yet another embodiment, a compound provided herein is administered subcutaneously. In still another embodiment, a compound provided herein is administered topically.
- a compound provided herein can be delivered as a single dose such as, e.g., a single bolus injection, or oral tablets or pills; or over time such as, e.g., continuous infusion over time or divided bolus doses over time.
- a compound provided herein can be administered repetitively, if necessary, for example, until the subject experiences stable disease or regression, or until the subject experiences disease progression or unacceptable toxicity.
- a compound provided herein can be administered once daily (QD) or divided into multiple daily doses such as twice daily (BID) , and three times daily (TID) .
- the administration can be continuous, i.e., every day, or intermittently.
- the term “intermittent” or “intermittently” as used herein is intended to mean stopping and starting at either regular or irregular intervals.
- intermittent administration of a compound provided herein is administration for one to six days per week, administration in cycles (e.g., daily administration for two to eight consecutive weeks, then a rest period with no administration for up to one week) , or administration on alternate days.
- a compound provided herein can also be combined or used in combination with other therapeutic agents useful in the treatment and/or prevention of a disease described herein.
- the compounds provided herein, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes, such as those exemplified herein.
- the reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
- suitable solvents can be substantially non-reactive with the starting materials (reactants) , the intermediates or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent’s freezing temperature to the solvent’s boiling temperature.
- a given reaction can be carried out in one solvent or a mixture of more than one solvent.
- suitable solvents for a particular reaction step can be selected by the skilled artisan.
- Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups.
- the need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
- the chemistry of protecting groups is described, e.g., in Kocienski, Protecting Groups, (Thieme, 2007) ; Robertson, Protecting Group Chemistry, (Oxford University Press, 2000) ; Smith el ah, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 8th Ed. (Wiley, 2019) ; Peturssion et al, "Protecting Groups in Carbohydrate Chemistry, " J Chem. Educ., 1997, 74 (11) , 1297; and Wuts et al., Protective Groups in Organic Synthesis, 5th Ed., (Wiley, 2014) .
- Reactions can be monitored according to any suitable method known in the art.
- product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C) , infrared spectroscopy, spectrophotometry (e.g., UV-visible) , or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
- spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C) , infrared spectroscopy, spectrophotometry (e.g., UV-visible) , or mass spectrometry
- chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
- ambient temperature e.g., a reaction temperature
- room temperature e.g., a temperature from about 20 °C to about 30 °C.
- heterocyclic amide derivatives of formula (I) can be prepared as the methods described in Scheme 1.
- Heterocyclic amide derivatives (I) can be prepared by reactions of carboxylic acids 1-1 with suitable 1, 3, 4-thiadiazol-2-amine derivatives 1-2 under standard amide coupling conditions (e.g., in the presence of an activating reagent such as BOP, PyBOP, HATU, HBTU, EDCI, or T 3 P and a base, such as Hunig’s base, Et 3 N, pyridine or DMAP) .
- an activating reagent such as BOP, PyBOP, HATU, HBTU, EDCI, or T 3 P
- a base such as Hunig’s base, Et 3 N, pyridine or DMAP
- a series of heterocyclic amide derivatives of formula (I) can be prepared as the methods described in Scheme 2.
- Amide derivatives 2-3 can be prepared by reactions of carboxylic acids 2-1 with suitable 1, 3, 4-thiadiazol-2-amine derivatives 2-2 in a similar manner as those described in the Scheme 1.
- a palladium catalyst such as Pd (OAc) 2 , Pd (dppf) Cl 2 , Pd 2 (dba) 3 , Pd (PPh 3
- a palladium catalyst such as Pd (OAc) 2 , Pd (dppf) Cl 2 , Pd 2 (dba) 3 , Pd (PPh 3
- a series of heterocyclic acid intermediates of formula 3-5 can be prepared as the methods described in Scheme 3.
- C-C coupling of compounds 3-1 with 3-3 can provide ester compounds 3-4 by the methods Suzuki coupling or Stille coupling as described in Scheme 2. Saponification of the compounds 3-4 can yield the corresponding acid 3-5 under a base such as LiOH, NaOH, KOH or Me 3 SnOH.
- Suzuki coupling of carboxylic acids 3-2 with compounds 3-3 can directly provide the corresponding acid 3-5 under standard Suzuki coupling conditions or Stille coupling conditions as described in Scheme 3.
- a series of 1, 3, 4-thiadiazol-2-amine derivatives of formula 4-3 can be prepared as the methods described in Scheme 4.
- Treatment of carboxylic acids 4-1 or cyanide 4-2 with thiosemicarbazide in the presence of a dehydrant such as POCl 3 , TFA, PCl 5 , P 2 O 5 or PPA can provide the 1, 3, 4-thiadiazol-2-amine derivatives 4-3.
- a series of 1, 3, 4-thiadiazol-2-amine derivatives of formula 5-4 can be prepared as the methods described in Scheme 5.
- Treatment of mono-ethyl difluoro-malonate 5-2 with thiosemicarbazide in the presence of a dehydrant such as POCl 3 , TFA, PCl 5 , P 2 O 5 or PPA can provide 1, 3, 4-thiadiazol-2-amine derivatives 5-4.
- condensations of compound 5-5 or mono-ethyl malonic chloride 5-6 with thiosemicarbazide can yield 1, 3, 4-thiadiazol-2-amine derivatives 5-7 which can be transformed into the 1, 3, 4-thiadiazol-2-amine derivatives 5-4 by treatment with a fluorination reagent such as N-fluorobenzenesulfonimide (NFSI) , and N-fluoropyridinum salts (NFPY) .
- a fluorination reagent such as N-fluorobenzenesulfonimide (NFSI) , and N-fluoropyridinum salts (NFPY) .
- 1, 3, 4-thiadiazol-2-amine derivatives 5-4 can be directly prepared from reactions of aminothiadiazole 5-8 with 2-bromo-2, 2-difluoroacetic acid esters 5-9 and H 2 O 2 in the presence of a catalyst such as Cp 2 Fe.
- Carboxic acids 6-2 can be prepared from C-C coupling of ethyl 2, 2-difluoro-2- (trimethylsilyl) acetate 6-1 with X-R AA where X is halo (e.g., Cl, Br, or I) or pseudohalogen (e.g., Otf or OMs) and R AA is C 0 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl or R 4 (wherein the C 0 -C 7 alkyl, C 2 -C 7 alkenyl, or C 2 -C 7 alkynyl is optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from R 4 ) in the presence of a suitable reagent such as KF or TBAF.
- Saponification of the compounds 6-2 can yield the corresponding acids 6-3 under basic conditions in the presence of a bas such as LiOH, NaOH, KOH or Me 3 SnOH.
- a bas such as LiOH, NaOH, KOH or Me 3 SnOH.
- Cyclization of the acids 6-3 with thiosemicarbazide can provide the corresponding 5- (difluoromethyl) -1, 3, 4-thiadiazol-2-amine derivatives 6-6 under the conditions as described in Scheme 4.
- 5- (difluoromethyl) -1, 3, 4-thiadiazol-2-amine derivatives 6-6 can be prepared from 5-amino-1, 3, 4-thiadiazol-2-one derivative 6-5 under an electrophilic fluorination reagent such as DAST, BAST, or XeF 2 .
- the 5-amino-1, 3, 4-thiadiazol-2-one derivatives 6-5 can be prepared by reaction of Weinreb amide compound 6-4 with organometallic reagents such as R AA MgBr under the conditions of standard Weinreb ketone synthesis.
- a series of 5- (difluoromethyl) -1, 3, 4-thiadiazol-2-amine derivatives of formula 7-4 can be prepared as the methods described in Scheme 7.
- C-O coupling of ethyl 2-bromo-2, 2-difluoroacetate 7-1 with HO-R A2 in the presence of a base such as Na 2 CO 3 , K 2 CO 3 , NaH, or t-BuOK can compounds 7-2.
- Saponification of the compounds 7-2 can yield the corresponding acids 7-3 in the presence of a base such as LiOH, NaOH, KOH or Me 3 SnOH.
- Cyclization of the acids 7-3 with thiosemicarbazide can produce the corresponding 5- (difluoromethyl) -1, 3, 4-thiadiazol-2-amine derivatives 7-4 under the conditions as described in Scheme 4.
- Example 1 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( ( (S) -tetrahydrofuran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 (S) -2- ( (tetrahydrofuran-3-yl) oxy) acetic acid
- Step 2 (S) -5- ( ( (tetrahydrofuran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-amine
- Step 3 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( ( (S) -tetrahydrofuran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 2 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( ( (R) -tetrahydrofuran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 3 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( (tetrahydro-2H-pyran-4-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 5- ( ( (tetrahydro-2H-pyran-4-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( (tetrahydro-2H-pyran-4-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 4 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( (-4-oxoadamantan-1-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 5- ( (5-amino-1, 3, 4-thiadiazol-2-yl) methoxy) adamantan-2-one
- Step 2 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( (-4-oxoadamantan-1-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 5 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( ( (-4-hydroxyadamantan-1-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 6 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( (tetrahydro-2H-pyran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 5- ( ( (tetrahydro-2H-pyran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( (tetrahydro-2H-pyran-4-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 7 4- (2-Fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( (tetrahydro-2H-pyran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 8 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (cyclohex-3-en-1-yloxy) methyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 2- ( (4- ( (tert-butyldimethylsilyl) oxy) cyclohexyl) oxy) acetic acid
- Step 2 5- ( (cyclohex-3-en-1-yloxy) methyl) -1, 3, 4-thiadiazol-2-amine
- Step 3 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (cyclohex-3-en-1-yloxy) methyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 9 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( ( (S) -1-tosylpyrrolidin-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 (S) -5- ( ( (1-tosylpyrrolidin-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( ( (S) -1-tosylpyrrolidin-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 10 4- (2-Fluoro-6-methoxyphenyl) -N- (5- (fluoromethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 2- (5- (hydroxymethyl) -1, 3, 4-thiadiazol-2-yl) isoindoline-1, 3-dione
- Step 2 2- (5- (fluoromethyl) -1, 3, 4-thiadiazol-2-yl) isoindoline-1, 3-dione
- Step 4 4- (2-fluoro-6-methoxyphenyl) -N- (5- (fluoromethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 11 4- (2-Fluoro-6-methoxyphenyl) -6-methyl-N- (5- (difluoromethyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 12 4- (2-Fluoro-6-methoxyphenyl) -6-methyl-N- (5- (trifluoromethyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 13 4- (2-Fluoro-6-methoxyphenyl) -6-methyl-N- (5- (pyridin-4-yl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 5- (pyridin-4-yl) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (pyridin-4-yl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 14 4- (2-Fluoro-6-methoxyphenyl) -N- (5- (4-methoxy-3-methylphenyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 5- (4-methoxy-3-methylphenyl) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (2-fluoro-6-methoxyphenyl) -N- (5- (4-methoxy-3-methylphenyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 15 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5-methyl-1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 16 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5-cyclopropyl-1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 17 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (difluoromethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 18 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5-isopropyl-1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 19 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5-ethyl-1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 20 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1-fluorocyclopropyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 5- (1-fluorocyclopropyl) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1-fluorocyclopropyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 21 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoroethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 5- (1, 1-difluoroethyl) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoroethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- This compound was prepared using procedures analogous to those described for Example 1 Step 3 using intermediate 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinic acid (Int-1) and 5- (1, 1-difluoroethyl) -1, 3, 4-thiadiazol-2-amine.
- Step 1 methyl 2'-chloro-5'-methoxy-6-methyl- [4, 4'-bipyridine] -3-carboxylate
- Step 2 2'-chloro-5'-methoxy-6-methyl- [4, 4'-bipyridine] -3-carboxylic acid
- Step 3 2'-chloro-N- (5- (ethylthio) -1, 3, 4-thiadiazol-2-yl) -5'-methoxy-6-methyl- [4, 4'-bipyridine] -3-carboxamide
- Example 23 4- (2, 3-Difluoro-6-methoxyphenyl) -6-methyl-N- (5- ( ( (tetrahydro-2H-pyran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 24 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (methoxymethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 25 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (ethoxymethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- (ethoxymethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 26 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( (2, 2, 2-trifluoroethoxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 5- ( (2, 2, 2-trifluoroethoxy) methyl) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( (2, 2, 2-trifluoroethoxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 27 4- (2-Fluoro-6-methoxy-3-methylphenyl) -6-methyl-N- (5- ( ( (tetrahydro-2H-pyran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 28 4- (2-Fluoro-6-methoxy-3- (trifluoromethyl) phenyl) -6-methyl-N- (5- ( ( (tetrahydro-2H-pyran-3-yl) oxy) methyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 29 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (2-methoxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 5- ( (2-methoxyethyl) thio) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (2-methoxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 30 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (ethylthio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- (ethylthio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 31 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( (2, 2, 2-trifluoroethyl) thio) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 5- ( (2, 2, 2-trifluoroethyl) thio) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( (2, 2, 2-trifluoroethyl) thio) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 32 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (2-hydroxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 5- ( (2- ( (tert-butyldimethylsilyl) oxy) ethyl) thio) -1, 3, 4-thiadiazol-2-amine
- Step 2 N- (5- ( (2- ( (tert-butyldimethylsilyl) oxy) ethyl) thio) -1, 3, 4-thiadiazol-2-yl) -4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamide
- Step 3 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (2-hydroxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 33 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (3-hydroxypropyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 34 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (3-hydroxy-3-methylbutyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 4- ( (5-amino-1, 3, 4-thiadiazol-2-yl) thio) -2-methylbutan-2-ol
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (3-hydroxy-3-methylbutyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 35 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (2-hydroxypropyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 36 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (3-cyanopropyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 4- ( (5-amino-1, 3, 4-thiadiazol-2-yl) thio) butanenitrile
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( (2, 2, 2-trifluoroethyl) thio) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 37 trans-4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (-2-hydroxycyclopentyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 trans-2- ( (5-amino-1, 3, 4-thiadiazol-2-yl) thio) cyclopentan-1-ol
- Step 2 trans-4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (-2-hydroxycyclopentyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 38 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (dimethylamino) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 N 2 , N 2 -dimethyl-1, 3, 4-thiadiazole-2, 5-diamine
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- (dimethylamino) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 39 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (methyl (2- (N-methylacetamido) ethyl) amino) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 tert-butyl (2- ( (5-amino-1, 3, 4-thiadiazol-2-yl) (methyl) amino) ethyl) (methyl) carbamate
- Step 2 tert-butyl (2- ( (5- (4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) (methyl) amino) ethyl) (methyl) carbamate
- Step 3 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (methyl (2- (methylamino) ethyl) amino) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 4 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (methyl (2- (N-methylacetamido) ethyl) amino) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 40 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (2-methoxyethyl) (methyl) amino) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 41 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (methyl (2, 2, 2-trifluoroethyl) amino) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 42 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (2-methoxyethyl) amino) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 43 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- ( (2, 2, 2-trifluoroethyl) amino) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 44 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (4-methyl-2-oxopiperazin-1-yl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 1- (5-amino-1, 3, 4-thiadiazol-2-yl) -4-methylpiperazin-2-one
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (4-methyl-2-oxopiperazin-1-yl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 45 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (methyl (2- (N-methylmethylsulfonamido) ethyl) amino) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 46 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (2- ( (N, N-dimethylsulfamoyl) (methyl) amino) ethyl) (methyl) amino) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 47 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (4-methyl-3-oxopiperazin-1-yl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 48 Ethyl 2- (5- (4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) -2, 2-difluoroacetate
- Step 1 ethyl 2- (5-amino-1, 3, 4-thiadiazol-2-yl) -2, 2-difluoroacetate
- Step 2 ethyl 2- (5- (4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) -2, 2-difluoroacetate
- Example 49 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoro-2-hydroxyethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 50 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoro-3-hydroxypropyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 5- (1, 1-difluorobut-3-en-1-yl) -1, 3, 4-thiadiazol-2-amine
- Step 2 3- (5-amino-1, 3, 4-thiadiazol-2-yl) -3, 3-difluoropropan-1-ol
- Step 3 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoro-3-hydroxypropyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 51 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluorobut-3-en-1-yl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 52 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluorobutyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 53 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (ethylsulfonyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 54 2- (5- (4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) -2, 2-difluoroacetic acid
- Example 55 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoro-2- (methylsulfonamido) -2-oxoethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 56 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (2- (dimethylamino) -1, 1-difluoro-2-oxoethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 57-100 listed in Table 1 below were prepared by using an intermediate ethyl 2- (5- (4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) -2, 2-difluoroacetate (Example 48) and an appropriate amine derivative as the methods analogous to those described for preparing Example 56.
- Example 101 N- (5- (2- (2-oxa-5-azabicyclo [2.2.1] heptan-5-yl) -1, 1-difluoro-2-oxoethyl) -1, 3, 4-thiadiazol-2-yl) -4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamide
- Step 1 2- (5- (4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) -2, 2-difluoroacetyl chloride
- Step 2 N- (5- (2- (2-oxa-5-azabicyclo [2.2.1] heptan-5-yl) -1, 1-difluoro-2-oxoethyl) -1, 3, 4-thiadiazol-2-yl) -4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamide
- Example 102-107 listed in Table 2 below were prepared by using an intermediate 2- (5- (4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) -2, 2-difluoroacetyl chloride (Example 101 Step 1) and an appropriate amine derivative or HCl salt thereof as the methods analogous to those described for preparing Example 101.
- Example 108 N- (5- (2- (Dimethylamino) -1, 1-difluoro-2-oxoethyl) -1, 3, 4-thiadiazol-2-yl) -4- (2-fluoro-6-methoxy-3-methylphenyl) -6-methylnicotinamide
- Step 1 ethyl 2, 2-difluoro-2- (5- (4- (2-fluoro-6-methoxy-3-methylphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) acetate
- Step 2 N- (5- (2- (dimethylamino) -1, 1-difluoro-2-oxoethyl) -1, 3, 4-thiadiazol-2-yl) -4- (2-fluoro-6-methoxy-3-methylphenyl) -6-methylnicotinamide
- Example 109 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoro-2- ( (7S, 8aS) -7- hydroxyhexahydropyrrolo [1, 2-a] pyrazin-2 (1H) -yl) -2-oxoethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 tert-butyl (7S, 8aS) -7- ( (4-nitrobenzoyl) oxy) hexahydropyrrolo [1, 2-a] pyrazine-2 (1H) -carboxylate
- Step 2 tert-butyl (7S, 8aS) -7-hydroxyhexahydropyrrolo [1, 2-a] pyrazine-2 (1H) -carboxylate
- Step 4 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoro-2- ( (7S, 8aS) -7-hydroxyhexahydropyrrolo [1, 2-a] pyrazin-2 (1H) -yl) -2-oxoethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 110 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoro-2-hydroxyethyl-2, 2-d2) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 111 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (perfluoroethyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 5- (perfluoroethyl) -1, 3, 4-thiadiazol-2-amine
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methyl-N- (5- (perfluoroethyl) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Example 112 3- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoroethyl) -1, 3, 4-thiadiazol-2-yl) isonicotinamide
- Step 1 methyl 3- (3-chloro-2-fluoro-6-methoxyphenyl) isonicotinate
- Step 3 3- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoroethyl) -1, 3, 4-thiadiazol-2-yl) isonicotinamide
- Example 113 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoroethyl) -1, 3, 4-thiadiazol-2-yl) -6- (1-methyl-1H-pyrazol-3-yl) nicotinamide
- Step 1 methyl 6-chloro-4- (3-chloro-2-fluoro-6-methoxyphenyl) nicotinate
- Step 2 methyl 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6- (1-methyl-1H-pyrazol-3-yl) nicotinate
- Step 3 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6- (1-methyl-1H-pyrazol-3-yl) nicotinic acid
- Step 4 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- (1, 1-difluoroethyl) -1, 3, 4-thiadiazol-2-yl) -6- (1-methyl-1H-pyrazol-3-yl) nicotinamide
- Example 114 Ethyl 2- ( (5- (4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) thio) propanoate
- Step 1 ethyl 2- ( (5-amino-1, 3, 4-thiadiazol-2-yl) thio) propanoate
- Step 2 ethyl 2- ( (5- (4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) thio) propanoate
- Example 115 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (1-hydroxypropan-2-yl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 116 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (1- (dimethylamino) -1-oxopropan-2-yl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 2- ( (5- (4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinamido) -1, 3, 4-thiadiazol-2-yl) thio) propanoic acid
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( (1- (dimethylamino) -1-oxopropan-2-yl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 2- ( (5-amino-1, 3, 4-thiadiazol-2-yl) thio) ethan-1-ol
- Step 2 methyl 4- (2-methoxyphenyl) -6-methylnicotinate
- Step 3 4- (2-methoxyphenyl) -6-methylnicotinic acid
- Step 4 N- (5- ( (2-hydroxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) -4- (2-methoxyphenyl) -6-methylnicotinamide
- Example 118 4- (5-Chloro-2-methoxyphenyl) -N- (5- ( (2-hydroxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 3 methyl 6-cyano-2- (2-methoxyphenyl) nicotinate
- Step 4 6-cyano-2- (2-methoxyphenyl) nicotinic acid
- Step 5 6-cyano-N- (5- ( (2-hydroxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) -2- (2-methoxyphenyl) nicotinamide
- Example 120 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -6-cyano-N- (5- ( (2-hydroxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 methyl 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-cyanonicotinate
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-cyanonicotinic acid
- Step 3 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-cyano-N- (5- ( (2-hydroxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) nicotinamide
- Step 1 ethyl 1- (2-methoxyphenyl) -1H-imidazole-5-carboxylate
- Step 2 1- (2-methoxyphenyl) -1H-imidazole-5-carboxylic acid
- Step 3 N- (5- ( (2-hydroxyethyl) thio) -1, 3, 4-thiadiazol-2-yl) -1- (2-methoxyphenyl) -1H-imidazole-5-carboxamide
- Example 122 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( ( (5-chloropyridin-2-yl) oxy) difluoromethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 cesium 2- ( (5-chloropyridin-2-yl) oxy) -2, 2-difluoroacetate
- Step 2 5- ( ( (5-chloropyridin-2-yl) oxy) difluoromethyl) -1, 3, 4-thiadiazol-2-amine
- Step 3 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( ( (5-chloropyridin-2-yl) oxy) difluoromethyl) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 123 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( ( (S) -2-hydroxypropyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 (S) -1- ( (5-amino-1, 3, 4-thiadiazol-2-yl) thio) propan-2-ol
- Step 2 4- (3-chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( ( (S) -2-hydroxypropyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Example 124 4- (3-Chloro-2-fluoro-6-methoxyphenyl) -N- (5- ( ( (R) -2-hydroxypropyl) thio) -1, 3, 4-thiadiazol-2-yl) -6-methylnicotinamide
- Step 1 methyl 5-chloro-2-methoxy-6'-methyl- [3, 4'-bipyridine] -3'-carboxylate
- Step 2 5-chloro-2-methoxy-6'-methyl- [3, 4'-bipyridine] -3'-carboxylic acid
- Step 3 5-chloro-N- (5- (1, 1-difluoroethyl) -1, 3, 4-thiadiazol-2-yl) -2-methoxy-6'-methyl- [3, 4'-bipyridine] -3'-carboxamide
- Step 1 (3-chloro-2-fluoro-6-methoxyphenyl) boronic acid
- Step 2 methyl 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinate
- Step 3 4- (3-chloro-2-fluoro-6-methoxyphenyl) -6-methylnicotinic acid
- Step 1 methyl 4- (2-fluoro-6-methoxyphenyl) -6-methylnicotinate
- Step 2 4- (2-fluoro-6-methoxyphenyl) -6-methylnicotinic acid
- Step 1 methyl 4- (2, 3-difluoro-6-methoxyphenyl) -6-methylnicotinate
- Step 2 4- (2, 3-difluoro-6-methoxyphenyl) -6-methylnicotinic acid
- Step 1 methyl 4- (2-fluoro-6-methoxy-3-methylphenyl) -6-methylnicotinate
- Step 2 4- (2-fluoro-6-methoxy-3-methylphenyl) -6-methylnicotinic acid
- Step 1 2- (3-fluoro-4- (trifluoromethyl) phenyl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane
- Step 4 (2-fluoro-6-methoxy-3- (trifluoromethyl) phenyl) boronic acid
- reaction mixture was quenched by aq HCl (2 M) solution (20 mL) at 0 °C, stirred for 30 min., and extracted with EtOAc (40 mL x 5) .
- EtOAc 40 mL x 5
- the combined organic layers were washed with brine (40 mL) , dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to afford the title compoud (2.0 g, 42%) as a yellow oil without further purification.
- Step 5 methyl 4- (2-fluoro-6-methoxy-3- (trifluoromethyl) phenyl) -6-methylnicotinate
- Step 6 4- (2-fluoro-6-methoxy-3- (trifluoromethyl) phenyl) -6-methylnicotinic acid
- Example A Biological evaluation
- PolQ ATPase activity was determined by ADP-Glo assay. 10-point dilution series of compounds were used in a 384 well format for the inhibition assays.
- PolQ (1-899) (1 nM) in assay buffer (20 mM Tris HCl (pH 8.0) , 80 mM KCl, 10 mM MgCl 2 , 1 mM DTT, 0.01%BSA, 0.01%Tween, 5%glycerol) was transferred to the test wells (20 uL) , except the low control wells (20 ⁇ L of assay buffer was added to the low control wells) . The plate was then incubated at room temperature for 30 min.
- IC 50 values were calculated using a four-parameter logistic curve fit using the following formula:
- IC 50 values were determined by fitting the data to the standard 4 parameters with Hill Slope using GraphPad Prism software. IC 50 : * ⁇ 10nM, 10nM ⁇ ** ⁇ 100nM, 100nM ⁇ *** ⁇ 500nM, ****>500nM. The experimental results of the compounds are described in Table 4.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des dérivés de thiadiazolyle, par exemple, un composé de formule (I), et des compositions pharmaceutiques de ceux-ci. L'invention concerne également leurs utilisations dans le traitement d'une maladie médiée par PolQ, par exemple, un cancer caractérisé par un défaut de réparation de l'ADN.
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2022/131231 | 2022-11-10 | ||
CN2022131231 | 2022-11-10 | ||
CNPCT/CN2023/079231 | 2023-03-02 | ||
CN2023079231 | 2023-03-02 | ||
CNPCT/CN2023/082601 | 2023-03-20 | ||
CN2023082601 | 2023-03-20 | ||
CNPCT/CN2023/088521 | 2023-04-14 | ||
CN2023088521 | 2023-04-14 | ||
CNPCT/CN2023/096096 | 2023-05-24 | ||
CN2023096096 | 2023-05-24 | ||
CN2023097515 | 2023-05-31 | ||
CNPCT/CN2023/097515 | 2023-05-31 | ||
CNPCT/CN2023/120729 | 2023-09-22 | ||
CN2023120729 | 2023-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024099337A1 true WO2024099337A1 (fr) | 2024-05-16 |
Family
ID=91031933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/130329 WO2024099337A1 (fr) | 2022-11-10 | 2023-11-08 | Dérivés de thiadiazolyle, compositions et utilisations associées |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024099337A1 (fr) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140221411A1 (en) * | 2011-10-21 | 2014-08-07 | Korea Research Institute Of Bioscience And Biotechnology | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient |
CN114127062A (zh) * | 2019-05-31 | 2022-03-01 | 伊迪亚生物科学有限公司 | 作为DNA聚合酶Theta抑制剂的噻二唑基衍生物 |
WO2022118210A1 (fr) * | 2020-12-02 | 2022-06-09 | Ideaya Biosciences, Inc. | Dérivés substitués de thiadiazolyle comme inhibiteurs de l'adn polymérase thêta |
WO2023050007A1 (fr) * | 2021-09-29 | 2023-04-06 | Repare Therapeutics Inc. | Composés n-([(l,3,4-thiadiazolyle) ou (thiazolyle)]-5-substitués)carboxamide (substitué) et leur utilisation pour inhiber la polymérase thêta humaine |
WO2023060573A1 (fr) * | 2021-10-15 | 2023-04-20 | Beijing Danatlas Pharmaceutical Co., Ltd. | Nouveaux dérivés du type thiadiazolyle d'inhibiteurs de l'adn polymérase thêta |
WO2023067515A1 (fr) * | 2021-10-22 | 2023-04-27 | Ideaya Biosciences, Inc. | Composés thiadiazolyles utilisés comme inhibiteurs de l'adn polymérase thêta |
WO2023202623A1 (fr) * | 2022-04-20 | 2023-10-26 | 南京再明医药有限公司 | Composé inhibiteur de polq et son utilisation |
-
2023
- 2023-11-08 WO PCT/CN2023/130329 patent/WO2024099337A1/fr unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140221411A1 (en) * | 2011-10-21 | 2014-08-07 | Korea Research Institute Of Bioscience And Biotechnology | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient |
CN114127062A (zh) * | 2019-05-31 | 2022-03-01 | 伊迪亚生物科学有限公司 | 作为DNA聚合酶Theta抑制剂的噻二唑基衍生物 |
WO2022118210A1 (fr) * | 2020-12-02 | 2022-06-09 | Ideaya Biosciences, Inc. | Dérivés substitués de thiadiazolyle comme inhibiteurs de l'adn polymérase thêta |
WO2023050007A1 (fr) * | 2021-09-29 | 2023-04-06 | Repare Therapeutics Inc. | Composés n-([(l,3,4-thiadiazolyle) ou (thiazolyle)]-5-substitués)carboxamide (substitué) et leur utilisation pour inhiber la polymérase thêta humaine |
WO2023060573A1 (fr) * | 2021-10-15 | 2023-04-20 | Beijing Danatlas Pharmaceutical Co., Ltd. | Nouveaux dérivés du type thiadiazolyle d'inhibiteurs de l'adn polymérase thêta |
WO2023061415A1 (fr) * | 2021-10-15 | 2023-04-20 | Danatlas Pharmaceuticals Co., Ltd. | Dérivés de thiadiazolyle, compositions et utilisations de ceux-ci |
WO2023067515A1 (fr) * | 2021-10-22 | 2023-04-27 | Ideaya Biosciences, Inc. | Composés thiadiazolyles utilisés comme inhibiteurs de l'adn polymérase thêta |
WO2023202623A1 (fr) * | 2022-04-20 | 2023-10-26 | 南京再明医药有限公司 | Composé inhibiteur de polq et son utilisation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109963842B (zh) | 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 | |
JP6133291B2 (ja) | ピラゾロ[3,4−c]ピリジン化合物と使用方法 | |
JP2022528562A (ja) | Mettl3阻害化合物 | |
JP2022524759A (ja) | Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 | |
JPWO2020004594A1 (ja) | 脊髄性筋萎縮症の予防または治療剤 | |
WO2022115377A1 (fr) | Dérivés de carboxamide tricycliques en tant qu'inhibiteurs de prmt5 | |
CN113061132B (zh) | 一类稠环内酰胺类化合物、制备方法和用途 | |
KR20160058188A (ko) | Btk의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도 | |
KR20190126344A (ko) | Fgfr 억제제 및 이의 용도 | |
AU2012310168B2 (en) | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase | |
AU2018389145B2 (en) | Exo-aza spiro inhibitors of menin-MLL interaction | |
BRPI0708615A2 (pt) | compostos de pirazol heterobicìclicos e métodos de uso | |
WO2015110999A1 (fr) | Inhibiteurs de ezh2 et leurs utilisations | |
TWI762534B (zh) | 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物 | |
TWI793704B (zh) | Sos1抑制劑、包含其的藥物組合物及其用途 | |
CN116635371A (zh) | 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途 | |
KR20230003161A (ko) | 브루톤의 티로신 키나제(btk) 억제제와 e3 리가제 리간드의 접합에 의한 btk의 분해 및 사용 방법 | |
CN117355532A (zh) | 三并环类usp1抑制剂及其用途 | |
WO2014072930A2 (fr) | Dérivés pyridine fondus, en tant qu'agents antibactériens | |
KR102351782B1 (ko) | 피리도 5원 방향족 고리계 화합물, 이의 제조 방법 및 용도 | |
CN109761986B (zh) | 三并环类衍生物抑制剂、其制备方法和应用 | |
WO2024099337A1 (fr) | Dérivés de thiadiazolyle, compositions et utilisations associées | |
TW202421623A (zh) | 噻二唑衍生物及其組合物和應用 | |
WO2024099336A1 (fr) | Dérivés de thiadiazolyle, compositions et utilisations de ceux-ci | |
CN117157299B (zh) | 三环杂环衍生物及其组合物和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23888026 Country of ref document: EP Kind code of ref document: A1 |